--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-KSB
(Mark One)
[X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE FISCAL YEAR ENDED DECEMBER 31, 2005
[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
FOR THE TRANSITION PERIOD FROM TO
COMMISSION FILE NUMBER: 000-23-661
------------
ROCKWELL MEDICAL TECHNOLOGIES, INC.
(Name of small business issuer in its charter)
MICHIGAN 38-3317208
(State or other jurisdiction of (I.R.S. employer
incorporation or organization) identification no.)
30142 WIXOM ROAD 48393
WIXOM, MICHIGAN (Zip code)
(Address of principal executive offices)
(248) 960-9009
(Issuer's telephone number, including area code)
SECURITIES REGISTERED PURSUANT TO SECTION 12(B) OF THE EXCHANGE ACT:
NONE
NAME OF EACH EXCHANGE ON WHICH REGISTERED:
SECURITIES REGISTERED PURSUANT TO SECTION 12 (G) OF THE EXCHANGE ACT:
COMMON SHARES, NO PAR VALUE
(Title of class)
COMMON SHARE PURCHASE WARRANTS
(Title of class)
Check whether the issuer is not required to file reports pursuant to
Section 13 or 15(d) of the Exchange Act. [ ]
Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90
days. YES [X] NO [ ]
Check if there is no disclosure of delinquent filers in response to Item
405 of Regulation S-B is not contained in this form, and no disclosure will be
contained, to the best of registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-KSB
or any amendment to this Form 10-KSB. [ ]
Indicate by a check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]
State issuer's revenues for its most recent fiscal year: $27,694,955
The aggregate market value of the voting and non voting common equity held
by non-affiliates computed by reference to the price at which our common shares
were last sold on March 3, 2006 was $45,539,511. In making this calculation, we
have excluded common shares held by our executive officers, directors and other
common shareholders with 5% or more of the common shares outstanding at December
31, 2005. Determination of common share holdings was determined by reference to
public filings, information provided to us by our transfer agent and discussions
with certain shareholders.
State the number of shares outstanding of each of the issuer's classes of
common equity as of the latest practicable date: 11,238,688 common shares
outstanding as of March 3, 2006.
Documents incorporated by reference: Portions of the Issuer's definitive
Proxy Statement pertaining to the 2006 Annual Meeting of Shareholders (the
"Proxy Statement") to be filed pursuant to Regulation 14A are herein
incorporated by reference to Parts III of this Report.
Transitional Small Business Disclosure Format (check
one). Yes [ ] No [X]
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
PART I
ITEM 1. DESCRIPTION OF BUSINESS.
Some of the statements in this report are forward-looking statements. These
forward-looking statements include certain statements contained in this
Description of our Business including, but not limited to, statements regarding
Fresenius Medical Care, Inc.'s acquisition of Renal Care Group, Inc., other
statements about our competitors, statements regarding the potential for the
Centers for Medicare and Medicaid Services to change its reimbursement policies
and the effect on our business of such change is made, and statements regarding
the timing and costs of obtaining FDA approval of our new iron product. In
addition, we may make forward-looking statements in future filings with the
Securities and Exchange Commission and in written material, press releases and
oral statements issued by us or on our behalf. Forward-looking statements
include statements regarding the intent, belief, or current expectations of us
or our officers, including statements preceded by , followed by or including
forward-looking terminology such as "may", "might", "will", "should", "believe",
"expect", "anticipate", "estimate", "continue", "predict", "forecast",
"projected" or similar expressions, with respect to various matters.
Our actual results might differ materially from those projected in the
forward-looking statements depending on various important factors. The important
factors include competition in our markets, our limited history of profitable
operations, the cost of obtaining FDA approval to market our new iron
supplemented dialysate product, the challenges associated with developing new
products, the uncertainty of the acceptance of our products by the hemodialysis
community, and other factors discussed in this report and other filings, all of
which constitute cautionary statements identifying important factors with
respect to forward-looking statements, including certain risks and
uncertainties, that could cause actual results to differ materially from those
in such forward-looking statements.
All forward-looking statements in this report are based on information
available to us on the date of this report. We do not undertake to update any
forward-looking statements that may be made by us or on our behalf in this
report or otherwise.
GENERAL
Rockwell Medical Technologies, Inc. (the "Company," "we," "us" and "our")
manufactures hemodialysis concentrates and dialysis kits, and we sell,
distribute and deliver these and other ancillary hemodialysis products to
hemodialysis providers in the United States, the Far East, eastern Europe and
Latin America. Hemodialysis duplicates kidney function in patients with failing
kidneys also known as End Stage Renal Disease (ESRD). Without properly
functioning kidneys, a patient's body cannot get rid of excess water and toxic
waste products. Without frequent and ongoing dialysis treatments these patients
would die.
We have also entered into two licensing agreements covering three U.S.
patents, two issued and one pending, as well as several foreign patents for iron
supplemented dialysate for treatment of iron deficiency in dialysis patients. We
are planning to conduct clinical trials of iron supplemented dialysate, which we
also refer to as dialysate iron and more specifically as Soluble Ferric
Pyrophosphate (SFP). To realize a commercial benefit from this therapy, and
pursuant to the license agreements, we must complete clinical trials and obtain
U.S. Food and Drug Administration ("FDA") approval to market iron supplemented
dialysate. We also plan to seek foreign market approval for this product. We
believe this product will substantially improve iron maintenance therapy and, if
approved, will compete for the global market for iron maintenance therapy. Based
on reports from manufacturers of IV iron products the market size in the United
States for this iron therapy is over $300,000,000 per year. We estimate the
global market is in excess of $500,000,000. We cannot, however, give any
assurance that this product will be approved by the FDA or, if approved, that it
will be successfully marketed.
HOW HEMODIALYSIS WORKS
Hemodialysis patients generally receive their treatments at independent
hemodialysis clinics or at hospitals. A hemodialysis provider such as a hospital
or a free standing clinic uses a dialysis station to treat patients. A dialysis
station contains a dialysis machine that takes concentrate solutions primarily
consisting of nutrients and minerals, such as our liquid concentrate solutions
or our concentrate powders mixed with purified water, and accurately
1
dilutes those solutions with purified water. The resulting solution, known as
dialysate, is then pumped through a device known as a dialyzer (artificial
kidney), while at the same time the patient's blood is pumped through a semi-
permeable membrane within the dialyzer. Excess water and chemicals from the
patient's blood pass through the membrane and are carried away in the dialysate
while certain nutrients and minerals in the dialysate penetrate the membrane and
enter the patient's blood to maintain proper blood chemistry. Dialysate
generally contains dextrose, sodium chloride, calcium, potassium, magnesium,
sodium bicarbonate and acetic acid. The patient's physician chooses the formula
required for each patient based on each particular patient's needs, although
most patients receive one of eight common formulations.
In addition to using concentrate solutions and chemical powders (which must
be replaced for each use for each patient), a dialysis provider also requires
various other ancillary products such as blood tubing, fistula needles,
specialized custom kits, dressings, cleaning agents, filtration salts and other
supplies, many of which we sell.
DIALYSIS INDUSTRY TRENDS
According to the latest statistics compiled by the Centers for Medicare and
Medicaid Services ("CMS"), the dialysis industry has experienced steady patient
population growth with the patient population increasing between 3-10% each year
over the last ten years. ESRD is an irreversible deterioration of kidney
function. Population segments with the highest incidence of ESRD are also the
fastest growing within the U.S. population including the elderly, Hispanic and
African-American population segments. During 2003, more than 82% of new ESRD
cases were primarily attributed to either diabetes (41.8%), hypertension (28.7%)
or glomerulonephritis (11.5%).
Hemodialysis providers are generally either independent clinics or
hospitals. According to CMS, since 1973 the total number of hemodialysis
providers in the United States increased from 606 in 1973 to 4,577 in December
2003. CMS also reports that the number of patients receiving hemodialysis has
also grown substantially in the last decade with annual patient growth averaging
5% and ranging from 3-10% each year. According to the CMS, in 2003, more than
311,000 patients were treated in Medicare-approved renal facilities as compared
to 157,525 patients in 1993 and, from 1993 to 2003, the number of hemodialysis
stations, which are areas equipped to provide adequate and safe dialysis
therapy, grew from 35,240 stations to 76,124 stations, or 116%. ESRD incidence
per annum in the United States was 347 per million of population. More than
100,000 patients began ESRD therapy in 2003.
ESRD incidence rates vary by country with some higher and some lower than
the United States. Based on industry reports, the global ESRD population is
estimated to be over 1.5 million
OUR STRATEGY
Our strategy is to develop our dialysis concentrate and supply business and
to develop drugs, nutrients and vitamins to be delivered by our dialysis
concentrate products. Our long term objectives are to increase our market share,
expand our product line, expand our geographical selling territory and improve
our profitability by implementing the following strategies:
- increasing our revenues through new innovative products, such as our Dri-
Sate(R) Dry Acid Concentrate and SteriLyte(R) Liquid Bicarbonate,
- gaining FDA approval to market innovative products such as iron
supplemented dialysate,
- acting as a single source supplier to our customers for the concentrates,
chemicals and supplies necessary to support a hemodialysis provider's
operation,
- increasing our revenues by expanding our ancillary product line,
- offering our customers a higher level of delivery and customer service by
using our own delivery vehicles and drivers, and
- expanding our market share in target regions, including regions where our
proximity to customers will provide us with a competitive cost advantage
and allow us to provide superior customer service levels.
2
PRODUCTS
We manufacture, sell, distribute and deliver hemodialysis concentrates as
well as a full line of ancillary hemodialysis products to hemodialysis providers
and distributors located in more than 35 states as well as a number of foreign
countries, primarily in the Far East, Eastern Europe and Latin America.
Hemodialysis concentrates are comprised of two primary product types, which are
generally described as acidified dialysate concentrate, also known as, acid
concentrate and bicarbonate.
ACID CONCENTRATE
Acid concentrate generally contains sodium chloride, dextrose and
electrolyte additives such as magnesium, potassium, and calcium. Acid
concentrate products are manufactured in three basic series to reflect the
dilution ratios used in various types of dialysis machines. We supply all three
series and currently manufacture approximately 60 different liquid acid
concentrate formulations. We supply liquid acid concentrate in both 55 gallon
drums and in cases containing four one gallon containers.
DRI-SATE(R) DRY ACID CONCENTRATE
In June of 1998, we obtained 510(k) clearance from the FDA to manufacture
and market Dri-Sate Dry Acid Concentrate. This product line enhanced our
previous liquid acid concentrate product offerings. Since its introduction, our
dry acid concentrate product line has been the primary catalyst behind our
growth.
Our Dri-Sate Dry Acid Concentrate allows a clinic to mix its acid
concentrate on-site. The clinical technician, using a specially designed mixer,
adds pre-measured packets of the necessary ingredients to 50 or 100 gallons of
purified water (AMII standard). Once mixed, the product is equivalent to the
acid concentrate provided to the clinic in liquid form. By using Dri-Sate Dry
Acid Concentrate numerous advantages are realized by the clinics including lower
cost per treatment, reduced storage space requirements, reduced number of
deliveries and more flexibility in scheduling deliveries. In addition to the
advantages to our customers, the freight costs to us are lower for Dri-Sate Dry
Acid Concentrate than for acid concentrate in the liquid form. We can also
realize greater productivity from our truck fleet resources delivering dry
products.
BICARBONATE
Bicarbonate is generally sold in powder form and each clinic generally
mixes bicarbonate on site as required. We offer approximately 20 bicarbonate
products covering all three series of generally used bicarbonate dilution
ratios.
STERILYTE(R) LIQUID BICARBONATE
In June of 1997, we obtained 510(k) clearance from the FDA to manufacture
and market SteriLyte Liquid Bicarbonate. Our SteriLyte Liquid Bicarbonate is
used in both acute care and chronic care settings. Our SteriLyte Liquid
Bicarbonate offers the dialysis community a high-quality product and provides
the clinic a safe supply of bicarbonate.
ANCILLARY PRODUCTS
We offer a wide range of ancillary products including blood tubing, fistula
needles, specialized custom kits, dressings, cleaning agents, filtration salts
and other supplies used by hemodialysis providers.
IRON SUPPLEMENTED DIALYSATE
We have licensed the exclusive right to manufacture and sell a product that
we believe will substantially improve the treatment of dialysis patients with
iron deficiency, which is pervasive in the dialysis patient population. Iron
deficiency in dialysis patients typically results from the demands placed upon
the body by current dialysis drug therapies. Most dialysis patients receive
replacement therapy of recombinant human erythropoetin (Epoetin alfa or EPO).
EPO is a hormone that acts in the bone marrow to increase the production of red
blood cells, which carry
3
oxygen throughout the body to nourish tissues and sustain life. Hemoglobin, an
important constituent of red blood cells, is composed largely of iron and
protein.
Treatment with EPO therapy requires adequate amounts of iron, as well as
the rapid mobilization of iron reserves, for new hemoglobin synthesis and new
red blood cell formation. The demands of this therapy can outstrip the body's
ability to mobilize iron stores. EPO is commonly administered as a large
intravenous injection on an intermittent basis, which creates an unnatural
strain on the iron release process when the need for iron outstrips its rate of
delivery, called functional iron deficiency. In addition, the majority of
dialysis patients also suffer from iron deficiency resulting from blood loss
from dialysis treatments and reduced dietary intake of iron. Accordingly, iron
supplementation is required to maintain proper iron balance and ensure good
therapeutic response from EPO treatments. The liver is the site of most stored
iron. Iron stores typically will be depleted before the production of iron-
containing proteins, including hemoglobin, is impaired. Most dialysis patients
receiving EPO therapy also receive iron supplement therapy in order to maintain
sufficient iron stores and to achieve the full benefit of EPO treatments.
Current iron supplement therapy involves intravenous parenteral iron
compounds, which deposit their iron load onto the liver rather than directly to
blood plasma to be carried to the bone marrow. The liver slowly processes these
iron deposits into a useable form. As a result of the time it takes for the
liver to process a dosage of intravenous iron into useable form, there can be
volatility in iron stores, which can reduce the effectiveness of EPO treatments.
Our iron supplemented dialysate is distinctly different from intravenous
iron compounds because our product transfers iron in a useable form directly
from dialysate into the blood plasma, from which it is carried directly to the
bone marrow for the formation of new red blood cells. The kinetic properties of
our iron compound allows for the rapid uptake of iron in blood plasma by
molecules that transport iron called transferrin. The frequency and dosage of
our iron supplemented dialysate is designed and intended to maintain iron
balance in a steady state. We believe that this more direct method of iron
delivery will be more effective at maintaining iron balance in a steady state
and to achieve superior therapeutic response from EPO treatments.
Iron supplemented dialysate has other benefits that we believe are
important. Iron administered by our product bypasses the liver altogether and
thereby avoids causing oxidative stress to the liver, which we believe is a
significant risk of current iron supplement therapies. In addition, we believe
that clinics may realize significant drug administration savings due to
decreased nursing time for administration and elimination of supplies necessary
to administer intravenous iron compounds.
We are currently in the process of preparing to seek FDA approval of iron
supplemented dialysate. A Phase II clinical trial on one of our licensed iron
supplemented dialysate products under an Investigational New Drug (IND)
exemption was completed by one of our licensors. We plan to conduct the testing
required to obtain FDA approval to market SFP in the United States. We began
safety and pharmacology testing in accordance with international standards and
FDA guidelines in the fourth quarter of 2005 and expect to complete these tests
in 2006. We plan to submit a Phase III protocol for FDA review in anticipation
of commencing Phase III clinical trials. We intend to commence Phase III
clinical trials after the FDA approves our Phase III protocol and conditioned
upon successful completion of safety and pharmacology testing.
We estimate the cost to obtain FDA approval from the beginning of 2006
through approval to be between $6-8 million. However, this estimate may be
modified as the approval process progresses. We will be required to pay the cost
of obtaining marketing approval of the product in order to realize any benefit
from commercialization of the product. In addition to funding, safety
pharmacology testing, clinical trials and patent maintenance expenses, we are
obligated to make certain milestone payments and to pay ongoing royalties upon
successful introduction of the product. The milestone payments include a payment
of $50,000 which will become due upon completion of Phase III clinical trials, a
payment of $100,000 which will become due upon FDA approval of the product and a
payment of $175,000 which will become due upon issuance of a reimbursement code
covering the product.
DISTRIBUTION AND DELIVERY OPERATIONS
The majority of our domestic sales are delivered by our subsidiary,
Rockwell Transportation, Inc. Rockwell Transportation, Inc. operates a fleet of
over 25 trucks which are used to deliver products to our customers. A portion
4
of our deliveries, primarily to medical products distributors, is provided by
common carriers chosen by us based on rates.
We perform services for customers that are generally not available from
common carriers, such as stock rotation, non-loading-dock delivery and drum
pump-offs. Certain of our competitors use common carriers and/or do not perform
the same services upon delivery of their products. We believe we offer a higher
level of service to our customers because of the use of our own delivery
vehicles and drivers.
If we are able to continue to grow our Dri-Sate Dry Acid Concentrate sales
and migrate our product mix from liquid acid dialysate in drums to Dri-Sate Dry
Acid Concentrate, we anticipate we will achieve improved distribution
efficiencies from our truck fleet as a result of reduced frequency of deliveries
and increased sales volume per truckload. As an example, a pallet containing
four drums of liquid acid concentrate contains 220 gallons of liquid acid
concentrate. On a pallet containing our Dri-Sate Dry Acid Concentrate, we can
ship the equivalent of 1,200 gallons of acid concentrate in powder form.
Our trucking operations are and will continue to be subject to various
state and federal regulations, which if changed or modified, could adversely
affect our business, financial condition and results of operations.
SALES AND MARKETING
We primarily sell our products directly to domestic hemodialysis providers
through three direct salespeople employed by us and through several independent
sales representation companies. Our President and Chief Executive Officer leads
and directs our sales efforts to our major accounts. We also utilize several
independent distributors in the United States. Our products are sold to certain
international customers through independent sales agents and distributors.
Our sales and marketing initiatives are directed at purchasing decision
makers at large for-profit national and regional hemodialysis chains and toward
independent hemodialysis service providers. Our marketing efforts include
advertising in trade publications, distribution of product literature and
attendance at industry trade shows and conferences. We target our sales and
marketing efforts to clinic administrators, purchasing professionals, nurses,
medical directors of clinics, hospital administrators and nephrologists.
COMPETITION
DIALYSIS CONCENTRATE AND SUPPLIES COMPETITION
We compete against larger more established competitors with substantially
greater financial, technical, manufacturing, marketing, research and development
and management resources. We compete against three major competitors, of which
our largest competitor is primarily in the business of operating hemodialysis
clinics. The two largest manufacturers of hemodialysis concentrates are
Fresenius Medical Care, Inc. ("Fresenius") and Gambro Healthcare, Inc.
("Gambro"). Fresenius is expected to be the largest operator of dialysis clinics
in the United States following its pending acquisition of Renal Care Group, Inc.
These competitors produce and sell a more comprehensive line of dialysis
equipment, supplies and services than we sell.
Fresenius treats over 89,000 dialysis patients in North America and
operates in over 1,150 clinics. It also has a renal products business that
manufactures a broad array of equipment and supplies including dialysis
machines, dialyzers (artificial kidneys), concentrates and other supplies used
in hemodialysis. In addition to its captive customer base in its own clinics,
Fresenius also serves other clinic chains and independent clinics with its broad
array of products. Fresenius manufactures its concentrate in its own regional
manufacturing facilities. Fresenius operates an extensive warehouse network in
the United States serving its captive customer base and other independent
clinics.
In May 2005, Fresenius announced its intention to acquire Renal Care Group,
Inc., the fourth largest provider of hemodialysis services in the United States.
Fresenius has indicated that it expects to complete this transaction on or prior
to the end of the first quarter of 2006. We believe that Fresenius currently
supplies the majority of Renal Care Group clinics with its products.
5
Gambro manufactures and sells hemodialysis machines, dialyzers and other
ancillary supplies. Gambro sells its concentrate solutions to dialysis chains
and independent clinics. Gambro sold products to its own clinics until October
2005 when it sold those clinics to DaVita, Inc., our largest customer. We
believe Gambro operates one manufacturing facility in Florida and additionally
uses other manufacturers, including a private label manufacturer in the eastern
United States to manufacture concentrate. Gambro also imports products from its
European manufacturing facilities. Gambro engages a third party trucking company
to deliver its products throughout the United States directly from the point of
manufacture and regional public and private warehouse locations. Gambro serves
the independent clinic market with liquid acid and powder bicarbonate
concentrate products used by its brand of dialysis machines as well as those
machines manufactured by its competitors in that segment. Gambro does not
manufacture a liquid bicarbonate product line.
In December 2004, Gambro announced its intention to sell its U.S. clinic
business to DaVita, Inc., our largest customer. This transaction was completed
in October of 2005 resulting in DaVita, Inc. having approximately 96,000
patients and 1,233 clinics. Gambro has entered into a supply agreement with
DaVita for certain dialysis products and supplies. The number of clinics to be
supplied and the type of products that will be supplied is not clear. It is not
clear how DaVita's acquisition of these clinics may impact our sales. We believe
these events may prove beneficial to our marketing efforts.
We also compete against Cantel Medical Corp.'s subsidiary, Minntech
Corporation ("Minntech"). Minntech's Renal Systems division primarily sells
dialysis concentrates and Renalin, a specialty reuse agent for sanitizing
dialyzers. We believe Minntech has one domestic manufacturing facility located
in Minnesota and a distribution center in Camp Hill, Pennsylvania. We believe
Minntech uses a private label manufacturer to supply certain products in the
northeastern United States to its warehouse. We believe Minntech largely uses
its own vehicles to deliver its products to its customers.
In addition, we compete against other distributors with respect to certain
ancillary products and supplies.
IRON MAINTENANCE THERAPY MARKET COMPETITION
We intend to enter the iron maintenance therapy market for the treatment of
dialysis patients with anemia. We must obtain FDA approval for our iron
supplemented dialysate to enter this market. The iron therapy market for
intravenous iron is serviced by two manufacturers. We believe the market leader
is Watson Pharmaceutical, Inc. ("Watson"). Watson markets a product called
Ferrlecit(R) which is an injectable iron supplement made of sodium ferric
gluconate complex in sucrose, and also markets a product called IN-FeD(R) which
is an injectable iron supplement made of dextran and ferric hydroxide. Watson is
a large manufacturer of both generic and branded drugs. A second competitor in
the intravenous iron market is American Regent Laboratories, Inc which markets
Venofer(R), an injectable iron sucrose product. Both Watson and American Regent
Laboratories, Inc. have substantially greater resources than us. American Regent
Laboratories, is a subsidiary of Luitpold, Inc. who has the U.S. marketing
rights for Venofer which was developed and is owned by the Galenica Group
through its subsidiary, Vifor International, Ltd.
The markets for drug products are highly competitive. New products we are
developing will face competition from both conventional forms of iron delivery
(i.e., oral and parenteral). In addition we believe that several companies
including Galenica are attempting to develop new IV iron drugs. Galenica has
commenced clinical studies on another parenteral iron product VIT-45. Advanced
Magnetics, Inc. is also developing an intravenous iron product.
Competition in drug delivery systems is generally based on marketing
strength, product performance characteristics (i.e., reliability, safety,
patient convenience) and product price. Acceptance by dialysis providers and
nephrologists is also critical to the success of a product. The first product on
the market in a particular therapeutic area typically is able to obtain and
maintain a significant market share. In a highly competitive marketplace and
with evolving technology, additional product introductions or developments by
others might render our products or technologies noncompetitive or obsolete. In
addition, pharmaceutical and medical device companies are largely dependent upon
health care providers being reimbursed by private insurers and government
agencies. Drugs approved by the FDA might not receive reimbursement from private
insurers or government
6
agencies. Even if approved by the FDA, providers of dialysate iron maintenance
therapy might not obtain reimbursement from insurers or government agencies. If
providers do not receive reimbursement for dialysate iron maintenance therapy,
the commercial prospects and marketability of the product would be severely
diminished.
CMS has historically paid providers for dialysis treatments in two parts;
the composite rate and separately reimbursed drugs and services. CMS
reimbursement practices are changing which we think may be beneficial in our
marketing efforts. CMS has already implemented a change in its reimbursement
practices by which it has reclassified the administration portion of drug
payments to the composite rate. Currently it is reimbursing separately for the
drug cost and has included the amount paid for drug administration into the
composite rate.
We believe that CMS payments to providers may eventually result in a single
composite rate per treatment, thereby eliminating reimbursement for individual
drugs. We believe that if and when a single reimbursement rate per treatment is
implemented by CMS that the provider market may view our iron supplemented
dialysate as an attractive alternative to IV iron drugs. Providers may be
attracted to our dialysate iron product over IV iron products due to lower cost
of administration and due to the potential of improved therapeutic response from
EPO treatments.
QUALITY ASSURANCE AND CONTROL
We place significant emphasis on providing quality products and services to
our customers. Quality management plays an essential role in determining and
meeting customer requirements, identifying, preventing and correcting variance
from specifications and improving our products. We have implemented quality
systems that involve control procedures that result in rigid conformance to
specifications. Our quality systems also include assessments of suppliers of raw
materials, packaging components and finished goods, and quality management
reviews designed to inform management of key issues that may affect the quality
of products, assess the effectiveness of our quality systems and identify areas
for improvement.
Technically trained professionals at our production facilities develop and
implement our quality systems which include specific product testing procedures
and training of employees reinforcing our commitment to quality and promoting
continuous process improvements. To assure quality and consistency of our
concentrates, we conduct specific analytical tests during the manufacturing
process for each type of product that we manufacture. Our quality control
laboratory at each facility conducts analytical tests to verify that the
chemical properties of the concentrates comply with the specifications required
by industry standards. Upon verification that a batch meets those
specifications, we then package those concentrates. We also test packaged
concentrates at the beginning and end of each production run to assure product
consistency during the filling process. Each batch is assigned a lot number for
tracking purposes and becomes available for shipment after verification that all
product specifications have been met.
We use automated testing equipment in order to assure quality and
consistency in the manufacture of our concentrates. The equipment allows us to
analyze the materials used in the hemodialysis concentrate manufacturing
process, to assay and adjust the in-process hemodialysis concentrate, and to
assay and certify that the finished products are within the chemical and
biological specifications required by industry regulations. Our testing
equipment provides us with a high degree of accuracy and efficiency in
performing the necessary testing.
GOVERNMENT REGULATION
The testing, manufacture and sale of our hemodialysis concentrates and the
ancillary products we distribute are subject to regulation by numerous
governmental authorities, principally the FDA and corresponding state and
foreign agencies. Under the Federal Food, Drug and Cosmetic Act (the "FDA Act"),
and FDA regulations, the FDA regulates the pre-clinical and clinical testing,
manufacture, labeling, distribution and promotion of medical devices.
Noncompliance with applicable requirements can result in, among other things,
fines, injunctions, civil penalties, recall or seizure of products, total or
partial suspension of production, failure of the government to grant pre-market
clearance or pre-market approval for devices, withdrawal of marketing clearances
or approvals and criminal prosecution.
We plan to develop and commercialize selected drug candidates by ourselves
such as our iron supplemented dialysate product. The regulatory review and
approval process, which includes preclinical testing and clinical trials
7
of each product candidate, is lengthy and uncertain. Before marketing in the
United States, any pharmaceutical or therapeutic product must undergo rigorous
preclinical testing and clinical trials and an extensive regulatory approval
process implemented by the FDA under the FDA Act.
Moreover, the FDA imposes substantial requirements on new product research
and the clinical development, manufacture and marketing of pharmaceutical
products, including testing and clinical trials to establish the safety and
effectiveness of these products.
MEDICAL DEVICE APPROVAL AND REGULATION
A medical device may be marketed in the United States only with prior
authorization from the FDA unless it is subject to a specific exemption. Devices
classified by the FDA as posing less risk than class III devices are categorized
as class I devices (general controls) or class II devices (general and specific
controls) and are eligible to seek "510(k) clearance". Such clearance generally
is granted when submitted information establishes that a proposed device is
"substantially equivalent" in intended use to a class I or II device already
legally on the market or to a "pre-amendment" class III device (i.e., one that
has been in commercial distribution since before May 28, 1976) for which the FDA
has not called for pre-market approval ("PMA") applications. The FDA in recent
years has been requiring a more rigorous demonstration of substantial
equivalence than in the past, including requiring clinical trial data in some
cases. For any devices that are cleared through the 510(k) process,
modifications or enhancements that could significantly affect safety or
effectiveness, or constitute a major change in the intended use of the device,
will require new 510(k) submissions. We have been advised that it now usually
takes from three to six months from the date of submission to obtain 510(k)
clearance, but it can take substantially longer. Our hemodialysis concentrates,
liquid bicarbonate and other ancillary products are categorized as class II
devices.
A device requiring prior marketing authorization that does not qualify for
510(k) clearance is categorized as class III, which is reserved for devices
classified by the FDA as posing the greatest risk (e.g., life-sustaining, life-
supporting or implantable devices), or devices that are not substantially
equivalent to a legally marketed class I or class II device. A class III device
generally must receive approval of a PMA application, which requires proving the
safety and effectiveness of the device to the FDA. The process of obtaining PMA
approval is expensive and uncertain. We have been advised that it usually takes
from one to three years after filing the request, but it can take longer.
If human clinical trials of a device are required, whether for a 510(k)
submission or a PMA application, and the device presents a "significant risk,"
the sponsor of the trial (usually the manufacturer or the distributor of the
device) will have to file an investigational device exemption ("IDE")
application prior to commencing human clinical trials. The IDE application must
be supported by data, typically including the results of animal and laboratory
testing. If the IDE application is approved by the FDA and one or more
appropriate Institutional Review Boards ("IRBs"), human clinical trials may
begin at a specific number of investigational sites with a specific number of
patients, as approved by the FDA. If the device presents a "non-significant
risk" to the patient, a sponsor may begin the clinical trial after obtaining
approval for the study by one or more appropriate IRBs without the need for FDA
approval.
Any devices manufactured or distributed by us pursuant to FDA clearances or
approvals are subject to pervasive and continuing regulation by the FDA and
certain state agencies. As a manufacturer of medical devices for marketing in
the United States we are required to adhere to regulations setting forth
detailed Good Manufacturing Practice ("GMP") requirements, which include
testing, control and documentation requirements. We must also comply with
Medical Device Reporting ("MDR") regulations which require that we report to the
FDA any incident in which our products may have caused or contributed to a death
or serious injury, or in which our products malfunctioned and, if the
malfunction were to recur, it would be likely to cause or contribute to a death
or serious injury. Labeling and promotional activities are subject to scrutiny
by the FDA and, in certain circumstances, by the Federal Trade Commission.
Current FDA enforcement policy prohibits the marketing of approved medical
devices for unapproved uses.
We are subject to routine inspection by the FDA and certain state agencies
for compliance with GMP requirements and other applicable Quality System
regulations. We are also subject to numerous federal, state and local laws
relating to such matters as safe working conditions, manufacturing practices,
environmental protection, fire hazard control, transportation and disposal of
hazardous or potentially hazardous substances.
8
We have 510(k) clearance from the FDA to market hemodialysis concentrates
in both liquid and powder form. In addition, we have received 510(k) clearance
for our Dri-Sate Dry Acid Concentrate Mixer.
We must comply with the FDA Act and related laws and regulations, including
GMP, to retain 510(k) clearances. We cannot assure you that we will be able to
maintain our 510(k) clearances from the FDA to manufacture and distribute our
products. If we fail to maintain our 510(k) clearances, we may be required to
cease manufacturing and/or distributing our products, which would have a
material adverse effect on our business, financial condition and results of
operations. If any of our FDA clearances are denied or rescinded, sales of our
products in the United States would be prohibited during the period we do not
have such clearances.
In addition to the regulations for medical devices covering our current
dialysate products, our new product development efforts will be subject to the
regulations pertaining to pharmaceutical products. We have signed licensing
agreements for iron supplemented dialysate to be included in our dialysate
products. Water soluble iron supplements when coupled with our dialysate will be
used as an iron maintenance therapy for dialysis patients, and we have been
advised that this dialysate iron product will be considered a drug/device
combination by the FDA. As a result, our iron maintenance therapy product will
be subject to the FDA regulations for pharmaceutical products, as well.
DRUG APPROVAL AND REGULATION
The marketing of pharmaceutical products, such as our new iron maintenance
therapy product, in the United States requires the approval of the FDA. The FDA
has established regulations, guidelines and safety standards which apply to the
pre-clinical evaluation, clinical testing, manufacturing and marketing of our
new iron maintenance therapy product and other pharmaceutical products. The
process of obtaining FDA approval for our new product may take several years and
involves the expenditure of substantial resources. The steps required before a
product can be produced and marketed for human use include: (i) pre-clinical
studies; (ii) submission to the FDA of an Investigational New Drug Exemption
("IND"), which must become effective before human clinical trials may commence
in the United States; (iii) adequate and well controlled human clinical trials;
(iv) submission to the FDA of a New Drug Application ("NDA") or, in some cases,
an Abbreviated New Drug Application ("ANDA"); and (v) review and approval of the
NDA or ANDA by the FDA. An NDA generally is required for products with new
active ingredients, new indications, new routes of administration, new dosage
forms or new strengths. An NDA requires that complete clinical studies of a
product's safety and efficacy be submitted to the FDA, the cost of which is
substantial. These costs can be reduced, however, for delivery systems which
utilize approved drugs.
An ANDA involves an abbreviated approval process that may be available for
products that have the same active ingredient(s), indication, route of
administration, dosage form and dosage strength as an existing FDA-approved
product, if clinical studies have demonstrated bio-equivalence of the new
product to the FDA-approved product. Under FDA ANDA regulations, companies that
seek to introduce an ANDA product must also certify that the product does not
infringe on the approved product's patent or that such patent has expired. If
the applicant certifies that its product does not infringe on the approved
product's patent, the patent holder may institute legal action to determine the
relative rights of the parties and the application of the patent, and the FDA
may not finally approve the ANDA until a court finally determines that the
applicable patent is invalid or would not be infringed by the applicant's
product.
Pre-clinical studies are conducted to obtain preliminary information on a
product's efficacy and safety. The results of these studies are submitted to the
FDA as part of the IND and are reviewed by the FDA before human clinical trials
begin. Human clinical trials may begin 30 days after receipt of the IND by the
FDA unless the FDA objects to the commencement of clinical trials.
Human clinical trials are typically conducted in three sequential phases,
but the phases may overlap. Phase I trials consist of testing the product
primarily for safety in a small number of patients at one or more doses. In
Phase II trials, the safety and efficacy of the product are evaluated in a
patient population somewhat larger than the Phase I trials. Phase III trials
typically involve additional testing for safety and clinical efficacy in an
expanded population at different test sites. A clinical plan, or protocol,
accompanied by the approval of the institution participating in the trials, must
be reviewed by the FDA prior to commencement of each phase of the clinical
trials. The FDA may order the temporary or permanent discontinuation of a
clinical trial at any time.
9
The results of product development and pre-clinical and clinical studies
are submitted to the FDA as an NDA or an ANDA for approval. If an application is
submitted, there can be no assurance that the FDA will review and approve the
NDA or an ANDA in a timely manner. The FDA may deny an NDA or an ANDA if
applicable regulatory criteria are not satisfied or it may require additional
clinical testing. Even if such data are submitted, the FDA may ultimately deny
approval of the product. Further, if there are any modifications to the drug,
including changes in indication, manufacturing process, labeling, or a change in
a manufacturing facility, an NDA or an ANDA supplement may be required to be
submitted to the FDA. Product approvals may be withdrawn after the product
reaches the market if compliance with regulatory standards is not maintained or
if problems occur regarding the safety or efficacy of the product. The FDA may
require testing and surveillance programs to monitor the effect of products
which have been commercialized, and has the power to prevent or limit further
marketing of these products based on the results of these post-marketing
programs.
The approval procedures for the marketing of our products in foreign
countries vary from country to country, and the time required for approval may
be longer or shorter than that required for FDA approval. Even after foreign
approvals are obtained, further delays may be encountered before products may be
marketed. For example, many countries require additional governmental approval
for price reimbursement under national health insurance systems.
Manufacturing facilities are subject to periodic inspections for compliance
with regulations and each domestic drug manufacturing facility must be
registered with the FDA. Foreign regulatory authorities may also have similar
regulations. We expend significant time, money and effort in the area of quality
assurance to insure full technical compliance. FDA approval to manufacture a
drug is site specific. In the event an approved manufacturing facility for a
particular drug becomes inoperable, obtaining the required FDA approval to
manufacture such drug at a different manufacturing site could result in
production delays, which could adversely affect our business and results of
operations.
OTHER GOVERNMENT REGULATIONS
The federal and state governments in the United States, as well as many
foreign governments, from time to time explore ways to reduce medical care costs
through health care reform. Due to uncertainties regarding the ultimate features
of reform initiatives and their enactment and implementation, we cannot predict
what impact any reform proposal ultimately adopted may have on the
pharmaceutical and medical device industry or on our business or operating
results. Our activities are subject to various federal, state and local laws and
regulations regarding occupational safety, laboratory practices, and
environmental protection and may be subject to other present and possible future
local, state, federal and foreign regulations.
PRODUCT LICENSE AGREEMENTS
We entered into two license agreements for iron supplemented dialysate
during 2001 and 2002, respectively. These license agreements cover both issued
and pending patents in the United States. These agreements also cover issued and
pending patents in a number of foreign jurisdictions. The license agreements
continue for the duration of the underlying patents in each country, or
approximately 13 years in the United States, and may be extended thereafter.
Patents were issued in the United States in 1999 and 2004. A European patent was
issued in 2005.
The product license agreements require us to obtain FDA approval of iron
supplemented dialysate. A Phase II clinical trial on one such iron supplemented
dialysate under an Investigational New Drug (IND) exemption was completed by one
of our licensors. We plan to conduct product testing and clinical trials in
order to obtain FDA approval to market this product. We will be required to pay
the cost of obtaining approval from the FDA to market the product in order to
realize any benefit from commercialization of the product which we estimate will
take several years and cost between $6 million and $8 million. In addition to
funding clinical trials and patent maintenance expenses, we are obligated to
make certain milestone payments and to pay ongoing royalties upon successful
introduction of the product as previously described.
10
TRADEMARKS & PATENTS
We have several trademarks and servicemarks used on our products and in our
advertising and promotion of our products, and we have applied for U.S.
registration of such marks. Most such applications have resulted in registration
of such trademarks and servicemarks.
We were issued a U.S. patent for our Dri-Sate Dry Acid Concentrate method
and apparatus for preparing liquid dialysate on May 28, 2002 which expires on
September 17, 2019. We have applied for corresponding international patents in
selected countries and these are pending at this time. In addition, we have a
pending patent application for packaging of ferric pyrophosphate for dialysis.
SUPPLIERS
We believe the raw materials for our hemodialysis concentrates, the
components for our hemodialysis kits and the ancillary hemodialysis products
distributed by us are generally available from several potential suppliers. Our
principal suppliers include, Cargill, Inc., Roquette, Inc., Church & Dwight Co.
Inc., Morton Salt Company and Nipro Medical Corporation.
CUSTOMERS
We operate in one market segment which involves the manufacture and
distribution of hemodialysis concentrates, dialysis kits and ancillary products
used in the dialysis process to hemodialysis providers. For the year ended
December 31, 2005, two customers each accounted for more than 10% of our total
sales, representing 55% of total sales. For the year ended December 31, 2004,
two customers each accounted for more than 10% of our total sales, representing
52% of total sales. Our accounts receivable from these customers were $840,000
and $1,362,000 as of December 31, 2005 and 2004, respectively. We are dependent
on these customers and the loss of any of them would have a material adverse
effect on our business, financial condition and results of operations. Our
international sales including products sold to domestic distributors that are
delivered internationally aggregated 28% and 4% of overall sales in 2005 and
2004, respectively.
EMPLOYEES
As of December 31, 2005, we had approximately 150 full time employees and
several part-time employees.
If our sales volumes continue to increase, we expect to add additional
production, distribution, sales and administrative personnel. Our arrangements
with our employees are not governed by any collective bargaining agreement. Our
employees are employed on an "at-will" basis.
Our employment agreements with Mr. Robert L. Chioini, our Chairman,
President and Chief Executive Officer and Mr. Thomas E. Klema, our Vice
President, Chief Financial Officer and Secretary have expired. Mr. Chioini and
Mr. Klema are continuing their employment without an employment agreement under
the same compensation terms.
RESEARCH & DEVELOPMENT
We have licensed an iron maintenance therapy product for the treatment of
iron deficiency in anemic dialysis patients which we refer to as iron
supplemented dialysate. We incurred expenses during 2005 and 2004 for product
development, to obtain regulatory approval and for regulatory maintenance of the
intellectual property underlying our licensing agreements. We engaged outside
consultants and legal counsel to assist us with product development and
obtaining regulatory approval. In addition, we incurred ongoing expenses related
to obtaining additional protection of the intellectual property underlying our
licensing agreements. In 2005 and 2004, we incurred expenses related to the
commercial development of our iron supplemented dialysate product aggregating
approximately $350,000 and $200,000, respectively.
We must undertake substantial testing to obtain FDA approval for our new
iron supplemented dialysate product. The cost of this testing including clinical
trials (which we estimate to be between $6 million and $8 million) will have a
material impact on us and we expect that we are likely to incur losses for the
duration of the clinical
11
trials. Should our testing and clinical trial expenses exceed our capital
resources, we may need to seek additional sources of financing to obtain FDA
approval of our new iron maintenance therapy product. If we are unable to obtain
FDA approval of our new iron maintenance therapy product or to make certain
milestone payments we may forfeit our rights under our license agreements.
Statements in this annual report concerning the timing of regulatory
filings and approvals are forward looking statements which are subject to risks
and uncertainties. The length of time necessary to complete product testing and
clinical trials, and from submission of an application for market approval to a
final decision by a regulatory authority, varies significantly. We might not
have the financial resources necessary to complete all of the testing and the
clinical trials for this product, and even if we do, they might not be
successfully completed. We might not be able to obtain regulatory approval for
any such product, and even if we do, any approved product might not be
successfully marketed. Similarly, our competitors, most of whom have greater
resources than us, might develop and introduce products that will adversely
affect our business and results of operations.
OTHER
We do not expect any significant cost or impact from compliance with
environmental laws.
WHERE YOU CAN GET INFORMATION WE FILE WITH THE SEC
We file annual, quarterly and current reports, proxy statements and other
information with the SEC. You can read and copy any materials we file with the
SEC at the SEC's Public Reference Room at 450 Fifth Street, N.W., Washington,
D.C. 20549. You may obtain information on the operation of the Public Reference
Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains a website on
the internet that contains reports, proxy and information statements and other
information regarding issuers, such as us, that file electronically with the
SEC. The address of the SEC's Web site is http://www.sec.gov.
We also maintain a website at http://www.rockwellmed.com. We make our
annual reports on form 10-KSB available free of charge on or through our
website.
ITEM 2. DESCRIPTION OF PROPERTY.
We entered into a lease agreement in October 2000 to lease a new 51,000
square foot facility in Wixom, Michigan. We occupied the new facility in July
2001 under a seven year lease. Base rent for the facility is $31,786 per month.
In addition, we are responsible for all property taxes, insurance premiums and
maintenance costs.
On March 12, 2000 we entered into an agreement to lease a 51,000 square
foot facility in Grapevine, Texas through August 2005. We renewed this lease
agreement for a term of five years expiring in August of 2010. Base monthly rent
for the facility in 2006 is $12,991, and we are responsible for all property
taxes, insurance premiums and maintenance costs. For periods after August 2007,
monthly rent is $13,630.
On February 23, 2005, we entered into a monthly lease agreement for a
61,000 square foot facility in Hodges, South Carolina. We entered into an
addendum to such lease agreement on December 12, 2005 which permits us to lease
the facility on a monthly basis. Monthly rent for the facility and certain
equipment in the facility is $37,500.
We intend to use all of our facilities to manufacture and warehouse our
products. We also use the office space in Wixom, Michigan as our principal
administrative office. We believe these facilities are suitable and adequate to
meet our current production and distribution requirements. However, should our
business continue to expand, we may require additional office space,
manufacturing capacity and distribution facilities to meet our requirements.
ITEM 3. LEGAL PROCEEDINGS
There are no material legal proceedings to which we are a party.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
We did not submit any matter to a vote of security holders during the
fourth quarter of 2005.
12
PART II
ITEM 5. MARKET FOR COMMON EQUITY AND RELATED SHAREHOLDER MATTERS.
Our common shares are traded on The Nasdaq Capital Market under the symbol
RMTI.
The prices below are the high and low bid prices as reported by The Nasdaq
Capital Market in each quarter during 2004 and 2005. The below prices reflect
inter-dealer prices, without retail mark-up, mark down or commission and may not
represent actual transactions.
BID PRICE
INFORMA-
TION
----------
QUARTER ENDED HIGH LOW
------------- ---- ----
March 31, 2004............................................... 4.50 3.45
June 30, 2004................................................ 4.25 2.52
September 30, 2004........................................... 3.41 2.28
December 31, 2004............................................ 3.75 2.67
March 31, 2005............................................... 3.90 2.79
June 30, 2005................................................ 3.49 2.60
September 30, 2005........................................... 4.25 2.76
December 31, 2005............................................ 5.13 3.40
As of March 3, 2006, there were 52 record holders of our common shares.
DIVIDENDS
Our Board of Directors has discretion whether or not to pay dividends.
Among the factors our Board of Directors considers when determining whether or
not to pay dividends are our earnings, capital requirements, financial
condition, future business prospects and business conditions. We have never paid
any cash dividends on our common shares and do not anticipate paying dividends
in the foreseeable future. We intend to retain earnings, if any, to finance the
development and expansion of our operations.
SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS
The following table summarizes our compensation plans under which our
equity securities are authorized for issuance as of December 31, 2005:
NUMBER OF SECURITIES TO BE NUMBER OF SECURITIES REMAINING
ISSUED UPON EXERCISE OF WEIGHTED AVERAGE EXERCISE AVAILABLE FOR FUTURE ISSUANCE UNDER
OUTSTANDING OPTIONS, PRICE OF OUTSTANDING OPTIONS, EQUITY COMPENSATION PLANS (EXCLUDING
WARRANTS AND RIGHTS WARRANTS AND RIGHTS SECURITIES REFLECTED IN COLUMN (A))
PLAN CATEGORIES (A) (B) (C)
--------------- -------------------------- ----------------------------- ------------------------------------
Equity compensation
plans approved by
security holders...... 3,359,335 $2.71 233,856
Equity compensation
plans not approved by
security holders...... -- -- --
Total................. 3,359,335 $2.71 233,856
RECENT SALES OF UNREGISTERED SECURITIES
On October 1, 2005, we issued 50,000 Common Shares pursuant to an election
to exercise Common Share Purchase Warrants which were acquired by an investor
during 2002 as part of a private placement of our Common Shares and such Common
Share Purchase Warrants. The offer and sale of the above Common Shares upon
exercise of the Common Share Purchase Warrants were exempt from the registration
requirements of the Securities Act of 1933 (the "Act") under Section 4(2) of the
Act. The issuance of such Common Shares was limited to persons
13
qualifying as "Accredited Investors" within the meaning of Regulation D under
the Act and were isolated transactions. We received $25,000 in gross proceeds
(or $.50 per share) as a result of the exercise of the Common Share Purchase
Warrants. Investors exercising these warrants received unregistered Common
Shares. The Common Share certificates issued contain a legend limiting their
transferability except in compliance with applicable state and Federal
securities laws.
PURCHASES OF EQUITY SECURITIES
(D)
(C) MAXIMUM NUMBER
TOTAL NUMBER OF (OR APPROXIMATE
SHARES (OR UNITS) DOLLAR VALUE) OF
(A) (B) PURCHASED AS PART SHARES (OR UNITS)
TOTAL NUMBER OF AVERAGE PRICE OF PUBLICLY THAT MAY YET BE
SHARES (OR UNITS) PAID PER SHARE ANNOUNCED PLANS OR PURCHASED UNDER THE
PERIOD PURCHASED (OR UNIT) PROGRAMS PLANS OR PROGRAMS
------ ----------------- -------------- ------------------ -------------------
Month #1 (beginning 3,270,303 Common Share (1) 3,270,303 Common Share 0
November 1, 2005 and Purchase Warrants with Purchase Warrants with
ended November 30, an exercise price of an exercise price of
2005)................ $4.50 per share. $4.50 per share.
Totals................. 3,270,303 3,270,303 0
--------
(1) Each Common Share Purchase Warrant with an exercise price of $4.50 per
share ("Old Warrants") was exchanged for a Common Share Purchase Warrant
("New Warrants") with an exercise price of $3.90 per share.
(2) The Company exchanged New Warrants for Old Warrants pursuant to a publicly
announced tender offer. The exchange offer covered up to a maximum amount
of 3,625,000 Old Warrants and was publicly announced on July 29, 2005. The
tender offer commenced on October 17, 2005 and expired on November 28,
2005. Holders of 3,270,303 Old Warrants tendered their Old Warrants and
were issued New Warrants in exchange therefor.
ITEM 6. MANAGEMENT'S DISCUSSIONS AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS.
OVERVIEW
We operate in a single business segment; the manufacture and distribution
of hemodialysis concentrates, dialysis kits and ancillary products used in the
dialysis process. We have gained market share each year since our inception in
1996. We increased our sales by 54% in 2005 over 2004 and have a five year
compound annual growth rate of sales of 30%. Our core concentrate sales grew 38%
in 2005. Net Income in 2005 was $76,800 or $.01 per share.
The dialysis supply market is very competitive and is characterized by
having a few dialysis providers treating the majority of patients in the United
States. We compete against companies which have substantially greater resources
than we have. Our revenue is highly concentrated in a few customers and the loss
of any of those customers would adversely affect our results. However, we expect
to continue to grow our business while executing our strategic plan to expand
our product lines, to expand our geographic reach and to develop our proprietary
technology which may include adding facilities and personnel to support our
growth. As we increase our business in certain markets and regions, we may incur
additional costs that are greater than the additional revenue generated from
these initiatives. We added a third manufacturing facility to support our growth
in 2005. Primarily as a result of expanding our production operations and higher
costs for fuel to deliver our products, our gross profit margins decreased in
2005.
We are seeking to gain FDA approval for our iron supplemented dialysate
product. We believe our iron supplemented dialysate product has the potential to
compete in the iron maintenance therapy market. If we are successful in
introducing our dialysate iron product, we believe it is possible that we may
also increase our market share for the other products we sell. The cost to
obtain regulatory approval for a drug in the United States is expensive and can
take a long time. We expect to spend between $6-8 million to complete testing
and file for regulatory approval in the United States. We completed an equity
financing transaction in January of 2006 which raised sufficient cash resources
to fund these expected costs.
14
We expect to incur substantial costs to conduct required clinical trials
and to obtain marketing approval which we expect will offset some or all of any
profits generated from sales of our existing products during the approval
process. We anticipate that we may report losses for the duration of the
approval process. We expect this process to take several years and we might not
be successful.
RESULTS OF OPERATIONS
FOR THE YEAR ENDED DECEMBER 31, 2005 COMPARED TO THE YEAR ENDED DECEMBER 31,
2004
Sales
For the year ended December 31, 2005, our sales were $27.7 million as
compared to sales of $17.9 million for 2004, representing an increase of 54.3%.
We increased our sales to our key national and regional chain customers. Sales
of our concentrate product lines increased by over 38% in 2005 over 2004 while
sales in our ancillary product lines increased by $3,600,000 in 2005 over 2004.
The increase in our ancillary product sales was primarily due to a single
purchase order for dialysis kits sold internationally.
Our core concentrate product lines which represented approximately 78% of
our total sales in 2005 increased by over 38% in 2005 over 2004. Sales of our
concentrate product lines were up over $6 million in 2005 over 2004 with our
growth due to unit volume increases in all of our product lines. Demand
increased for all of our concentrate product lines with substantial growth in
both powder and liquid product lines. New business gained in 2005 was
predominated by accounts using liquid products. Both domestic and international
growth was largely liquid concentrate business with approximately 70% of the
dollar value of our concentrate growth in liquid concentrates in 2005.
Our ancillary product sales grew substantially with the majority of the
growth due to a single purchase order by a distributor for specialty dialysis
kits sold internationally. We anticipate orders from this distributor to recur
in 2006. However, the timing and recurrence of such orders may result in
volatility in order patterns for our products possibly causing our sales to this
distributor to fluctuate between interim periods unlike the majority of our
domestic based customers who order on a consistent routine pattern.
Gross Profit
Gross profit was $3,005,000 which increased by $200,000 in 2005 as compared
to 2004. While the absolute amount of gross profit increased our gross profit
margins decreased. We added a facility in the Southeastern United States in
March of 2005 to manufacture and distribute products to our business in that
region. Most of the accounts we added in the Southeastern United States in 2005
had historically used liquid acid concentrate products. While we reduced our
distribution costs in that region, the infrastructure and fixed costs we added
were only partially offset by increased sales volumes. As a result, our overall
gross profit margins decreased.
Our gross profit margins decreased by 4.8 percentage points to sales in
2005 compared to 2004. Increased fuel costs to deliver our products accounted
for one third of the decrease of 1.6 percentage points to sales. The remainder
of the decrease in gross profit margins was due to the addition of fixed costs
for facilities, personnel and equipment used to support our growth. While these
costs were fully funded by the incremental gross profit generated by our
increased concentrate product sales, the overall gross profit margins decreased
due to the additional production resources that were added in 2005. In addition,
we experienced higher than usual production and distribution costs resulting
from short term volatility in order patterns from certain customers.
Selling, General and Administrative Expenses
Selling, General and Administrative expenses were $2,867,800 and were 10.4%
of sales, a reduction of 3.1 percentage points to sales compared to 2004. While
the expense ratio to sales improved the absolute amount of costs increased by
$471,000 or 20%. Increased spending on research and development of dialysate
iron accounted for $150,000 of the increase and the remainder of $321,000 was
for increased costs to develop and administer the substantial growth in our
business including additional resources and expenses. Total expenses increased
in 2005 over 2004 due to additional personnel costs and increased spending on
information systems to handle increased transaction activity associated with our
38% increase in concentrate sales.
15
We made a considerable investment for research and product development of
dialysate iron in 2005 with aggregate spending of $350,000. We spent over
$200,000 for development of our iron supplemented dialysate product in 2004. We
expense these investments in the year they are incurred.
Other Income
We were the plaintiff in certain litigation that was settled in the first
quarter of 2005. We have recognized $137,468 of other income from this
settlement.
Operating Income
Our Operating Income in 2005 was $137,000 or .5% of sales and decreased by
$272,000 compared to 2004. The decrease in operating income was due to the
higher spending for research and product development costs of $150,000 and the
remainder of the decrease due to increased spending to support our expansion and
development.
Interest Expense
Interest expense remained approximately the same in 2005 compared to 2004
as higher borrowings offset the impact of lower interest rates under our new
line of credit.
Net Income
Net income in 2005 was $76,800 or $.01 per share. We have substantial tax
loss carryforwards from our earlier losses and the impact of those carryforward
losses offset our statutory tax liability for 2005. We have not recorded a
federal income tax benefit from our prior losses because we might not realize
the carryforward benefit of the remaining losses.
Basic earnings per share was $.01 for 2005 which was a $.01 decrease from
2004. We increased spending on product development in 2005 compared to 2004 by
the equivalent of $.02 per share. Similarly, fully diluted earnings per share in
2005 of $.01 was $.01 lower as compared to 2004.
FOR THE YEAR ENDED DECEMBER 31, 2004 COMPARED TO THE YEAR ENDED DECEMBER 31,
2003
Sales
For the year ended December 31, 2004, our sales were $17.95 million as
compared to sales of $15 million for 2003, representing an increase of 19.9%. We
increased our sales to our key national and regional chain customers. Sales of
our concentrate product lines increased by over 30% while sales in our ancillary
product lines decreased by $600,000. The decrease in our ancillary product sales
was due to a reduction in blood tubing sales to a single customer of $860,000 in
2004 as compared to 2003.
Our core concentrate product lines which represented approximately 85% of
our total sales in 2004 increased by over 30% over 2003. Sales of our
concentrate product lines were up $3.6 million in 2004 over 2003. Demand
increased for all of our concentrate product lines with substantial growth in
both powder and liquid product lines. Both clinic chains and independent
providers are attracted to our Dri-Sate product line and its patented Dri-
Sate(R) Dry Acid Concentrate Mixing System. Our Dri-Sate Dry Acid Concentrate
unit volumes increased 38% over 2003. Similarly, our gallon volume of liquid
acid concentrate grew by 40%. Our SteriLyte(R) Liquid Bicarbonate unit volume
increased 52% in 2004 as compared to 2003. Powder bicarbonate unit volumes
increased by 32%.
While our overall ancillary sales declined in 2004 as compared to 2003 due
to the reduction in blood tubing purchases by a single customer of $860,000, the
remainder of our ancillary products realized increases in sales volumes. We
realized additional blood tubing sales aggregating $150,000 and we experienced
an increase of $110,000 in specialty kit sales.
We also experienced a reduction in backhaul revenue from our transportation
fleet. Our backhaul revenue declined $67,000 in 2004 as compared to 2003 as a
result of a combination of factors including new driver regulations that reduced
the amount of driving time available and due to the significant business growth
we realized
16
that resulted in greater utilization of our fleet to deliver our own products.
We do not expect backhaul revenue to be a material source of revenue in the
future.
Gross Profit
Gross profit was $2,805,000 and increased by $250,000 in 2004 as compared
to 2003. In 2004, we made a change to the relative allocation of certain costs
for facility, depreciation and other costs that increased the portion of those
costs included in cost of goods sold. As a result, we increased cost of sales by
$136,800 in 2004 as compared to 2003 or .8% of sales for this change in
allocations. Overall, our comparable gross profit margins between 2004 and 2003
decreased by .5 percentage points after adjusting for this change in
allocations. Despite higher sales volumes, our gross profit margins of 15.6%
decreased largely due to increased delivery costs for our products which more
than offset productivity improvements from higher production volumes.
We experienced substantially higher delivery costs throughout 2004 due to
several contributing factors including additional fleet resources added to
support new business growth, higher fuel costs to operate our fleet, increased
frequency of deliveries for certain customers and in the second half of 2004 a
higher growth rate in customers in territories beyond our traditional
distribution footprint. As a result of a combination of these factors, our
distribution costs were up approximately 3 percentage points to sales as
compared to 2003. We have added a new facility in the Southeast to reduce
distribution costs of our products in that region.
Selling, General and Administrative Expenses
Selling, General and Administrative expenses were $2,396,000 and were 13.4%
of sales, an improvement of 2.4 percentage points compared to 2003. However, we
reduced the allocation of facility, depreciation and other costs charged to
selling, general and administrative expense by $136,800. Without this allocation
change, selling, general and administrative costs increased by $165,000, or 7%
compared to 2003. The majority of the cost increase was due to additional
resources and expenses, including additional personnel costs, to handle
increased transaction activity associated with our 30% increase in concentrate
sales.
We made a considerable investment for research and product development of
dialysate iron in 2004 with aggregate spending of $200,000. We spent over
$250,000 for development of our iron supplemented dialysate product in 2003. We
expense these investments in the year they are incurred.
Operating Income
Our Operating Income in 2004 increased over our operating income in 2003 by
$221,000 or 118% to $409,000 or 2.3% of sales. This improvement resulted
primarily from our increased sales volumes.
Interest Expense
Interest expense increased by $14,600 in 2004 over 2003 due to higher
interest expense on new capitalized leases obligations. This increase was
partially offset by lower average borrowings under our line of credit.
Net Income
Net income in 2004 was $211,522, an improvement of $206,700 over 2003. Net
income to sales improved by 1.2 percentage points to sales compared to 2003. We
have substantial tax loss carryforwards from our earlier losses and the impact
of those carryforward losses offset the statutory tax liability for 2004. We
have not recorded a federal income tax benefit from our prior losses because we
might not realize the carryforward benefit of the remaining losses.
Basic earnings per share was $.02 which was a $.02 improvement in net
income per share in 2004 over 2003. Similarly, fully diluted earnings per share
of $.02 improved $.02 as compared to 2003.
17
CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS
Our consolidated financial statements and accompanying notes are prepared
in accordance with accounting principles generally accepted in the United States
of America.
These accounting principles require us to make estimates, judgments and
assumptions that affect the reported amounts of revenues, expenses, assets,
liabilities, and contingencies.
All significant estimates, judgments and assumptions are developed based on
the best information available to us at the time made and are regularly reviewed
and updated when necessary. Actual results will generally differ from these
estimates. Changes in estimates are reflected in our financial statements in the
period of change based upon on-going actual experience, trends, or subsequent
realization depending on the nature and predictability of the estimates and
contingencies.
Interim changes in estimates are generally applied prospectively within
annual periods. Certain accounting estimates, including those concerning revenue
recognition and allowance for doubtful accounts, impairments and valuation
adjustments, and accounting for income taxes, are considered to be critical in
evaluating and understanding our financial results because they involve
inherently uncertain matters and their application requires the most difficult
and complex judgments and estimates.
Revenue recognition and allowance for doubtful accounts
We recognize revenue at the time we transfer title to our products to our
customers consistent with generally accepted accounting principles. Our products
are generally sold domestically on a delivered basis and as a result we do not
recognize revenue until delivered to the customer with title transferring upon
completion of the delivery. For our international sales, we generally transfer
title to the buyer when the container leaves our facility and therefore we
recognize revenue upon shipment to foreign customers. We also recognize revenue
for delivery of freight for third parties upon completion of the delivery
service.
Accounts receivable are stated at invoice amounts. The carrying amount of
trade accounts receivable is reduced by an allowance for doubtful accounts that
reflects our best estimate of accounts that may not be collected. We review
outstanding trade account receivable balances and based on our assessment of
expected collections, we estimate the portion, if any, of the balance that may
not be collected as well as a general valuation allowance for other accounts
receivable based primarily based on historical experience. All accounts or
portions thereof deemed to be uncollectible are written off to the allowance for
doubtful accounts.
Impairments of long-lived assets
We account for impairment of long-lived assets, which include property and
equipment, amortizable intangible assets and goodwill, in accordance with the
provisions of SFAS No. 144 Accounting for the Impairment or Disposal of Long-
Lived Assets or SFAS No. 142 Goodwill and Other Intangible Assets, as
applicable. An impairment review is performed annually or whenever a change in
condition occurs which indicates that the carrying amounts of assets may not be
recoverable. Such changes may include changes in our business strategies and
plans, changes to our customer contracts, changes to our product lines and
changes in our operating practices. We use a variety of factors to assess the
realizable value of long-lived assets depending on their nature and use.
Goodwill is not amortized; however, it must be tested for impairment at
least annually. The goodwill impairment analysis is based on the fair market
value of our common shares. Amortization continues to be recorded for other
intangible assets with definite lives over the estimated useful lives.
Intangible assets subject to amortization are reviewed for potential impairment
whenever events or circumstances indicate that carrying amounts may not be
recoverable based on future cash flows.
Accounting for income taxes
We estimate our income tax provision to recognize our tax expense and our
deferred tax liabilities and assets for future tax consequences of events that
have been recognized in our financial statements using current enacted tax laws.
Deferred tax assets must be assessed based upon the likelihood of recoverability
from future taxable income
18
and to the extent that recovery is not likely, a valuation allowance is
established. The allowance is regularly reviewed and updated for changes in
circumstances that would cause a change in judgment about whether the related
deferred tax asset may be realized. These calculations and assessments involve
complex estimates and judgments because the ultimate tax outcome can be
uncertain and future events unpredictable.
LIQUIDITY AND CAPITAL RESOURCES
Our strategy includes expanding our operations and seeking FDA approval for
our iron supplemented dialysate product. We believe that we can continue to grow
and expand our business. We plan to develop and offer new and innovative
products to the dialysis market. We expect that we will continue to realize
substantial sales growth in the future. In 2005, our revenue increased by
$9,750,245 or 54.3% over 2004.
In January of 2006, prior to expiration of common share purchase warrants
we issued in November of 2005 ("New Warrants") in exchange for most of our
previously outstanding common share purchase warrants, most of the holders of
such New Warrants exercised the New Warrants from which we realized gross
proceeds of $9.3 million. We believe these proceeds will fund all of our
foreseeable cash requirements in 2006.
We have two major areas of strategic focus in our business. First, we plan
to develop our dialysis concentrate solutions and ancillary supply business.
Second, we plan to expand our product offering to include drugs and vitamins
administered to dialysis patients.
Our plan is to expand our operations to serve dialysis providers throughout
the United States and internationally on an export basis. We anticipate that, as
a result of our existing supply agreements, our customer relationships and our
changing market dynamics, we have the opportunity to capture substantial market
share that will lead to sustaining and increasing our profitable operations. We
expect that we will continue to realize substantial growth during 2006 and that
we will require additional working capital and capital expenditures to fund this
growth. In order to fund facility expansions and certain capital expenditures,
we intend to enter into lease financing arrangements. We anticipate that our
working capital line of $2.75 million is sufficient to meet our requirements for
working capital expansion in the year ahead.
The dialysis provider industry that we serve is becoming increasingly
concentrated. As a result, our business is predominantly with national and
regional dialysis chains. If we were to lose a significant portion of our
business with major national and regional dialysis chains, it could have a
substantial negative impact on our cash flow and results. If we were to lose a
substantial portion of our business, it may have a detrimental impact on our
ability to continue our operations in their current form or to continue to
execute our business strategy. If we lost a substantial portion of our business,
we would be required to take actions to conserve our cash resources and to
mitigate the impact of any such losses on our business operations.
Our second major area of focus is to expand our product offering to include
drugs and vitamins administered to dialysis patients using our dialysis
concentrate solutions as the delivery method. We are seeking FDA approval for
our dialysate iron drug product. The development and approval of drugs can be
expensive and take a long time. Drug development and approval costs may offset
some or all of any earnings during the approval process and we may incur losses
in the future. We estimate the cash required to fund development and approval of
our new iron supplemented dialysate product will be between
$6,000,000 -- $8,000,000 over the next several years. We expect to spend between
$3,000,000 -$4,000,000 in 2006 on product testing and possibly more depending on
the progress of testing during the year.
To fund our business development efforts for our two key areas of focus we
completed an equity offering of our common shares under which our publicly
traded warrants were exercised for common shares. We issued 2,401,021 Common
shares at $3.90 per common shares resulting in gross proceeds of $9,363,000 with
$9,135,000 raised in January 2006. These substantial cash resources are intended
to be used for our business development initiatives. We anticipate that the net
proceeds from this offering will be sufficient for us to complete the FDA
approval process for our dialysate iron product. However, there is no guarantee
that we will not require additional funds to execute our strategy or pursue
other business development opportunities. If we need additional funds in the
future, we will evaluate both debt and equity financing as potential sources of
funds.
19
In December 2004, the Financial Accounting Standards Board ("FASB") issued
Statement No. 123R ("SFAS 123R"), a revision to Statement No. 123, "Accounting
for Stock-Based Compensation." This standard requires us to measure the cost of
employee services received in exchange for equity awards, including stock
options, based on the grant date fair value of the awards. The cost will be
recognized as compensation expense over the vesting period of the awards. The
Company is required to adopt SFAS 123R beginning January 1, 2006. The standard
provides for a modified prospective application. Under this method, we will
begin recognizing compensation cost for equity based compensation for all new or
modified grants after the date of adoption. In addition, the standard requires
us to recognize compensation cost for the remaining unvested portion of prior
option grants over the remaining service period. However, all of our options
granted in 2005 and prior years have been fully vested as of December 31, 2005.
We accelerated vesting with the intent that no expense would be recognized upon
adoption of SFAS 123R for option grants from 2005 and prior years.
ITEM 7. FINANCIAL STATEMENTS
The Consolidated Financial Statements of the Registrant required by this
item are set forth on pages F-1 through F-16.
ITEM 8. CHANGES AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
DISCLOSURE
None.
ITEM 8A. CONTROLS AND PROCEDURES
(a) Evaluation of disclosure controls and procedures.
We carried out an evaluation under the supervision and with the
participation of our management, including our Chief Executive Officer and Chief
Financial Officer, of the effectiveness of our disclosure controls and
procedures as of December 31, 2005. Based upon that evaluation, our Chief
Executive Officer and Chief Financial Officer concluded that our disclosure
controls and procedures are effective as of December 31, 2005 in ensuring that
information required to be disclosed by us under the Exchange Act is recorded,
processed, summarized and reported within the time periods specified under the
Exchange Act rules and forms. There was no change in our internal control over
financial reporting identified in connection with such evaluation that occurred
during our fiscal quarter ended December 31, 2005 that has materially affected,
or is reasonably likely to materially affect, our internal control over
financial reporting.
Disclosure controls and procedures are our controls and other procedures
that are designed to ensure that information required to be disclosed by us in
the reports that we file or submit under the Exchange Act is recorded,
processed, summarized and reported, within the time periods specified in the
Securities and Exchange Commission's rules and forms. Disclosure controls and
procedures include, without limitation, controls and procedures designed to
ensure that information required to be disclosed by us in the reports that we
file or submit under the Exchange Act is accumulated and communicated to our
management, including our principal executive and principal financial officers,
as appropriate to allow timely decisions regarding required disclosure.
(b) Changes in internal controls.
The Company maintains a system of internal controls that are designed to
provide reasonable assurance that its books and records accurately reflect the
Company's transactions and that its established policies and procedures are
followed. For the quarter ended December 31, 2005, there were no significant
changes to the Company's internal controls or in factors that could
significantly affect the Company's internal controls.
ITEM 8B. OTHER INFORMATION
None.
20
PART III
ITEM 9. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS;
COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT.
Incorporated herein by reference to Rockwell Medical Technologies, Inc.
definitive proxy statement to be filed with the Securities and Exchange
Commission within 120 days after the year covered by this Form 10-KSB with
respect to its Annual Meeting of Shareholders to be held on May 25, 2006.
ITEM 10. EXECUTIVE COMPENSATION.
Incorporated herein by reference to Rockwell Medical Technologies, Inc.
definitive proxy statement to be filed with the Securities and Exchange
Commission within 120 days after the year covered by this Form 10-KSB with
respect to its Annual Meeting of Shareholders to be held on May 25, 2006.
ITEM 11. SECURITIES OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.
Incorporated herein by reference to Rockwell Medical Technologies, Inc.
definitive proxy statement to be filed with the Securities and Exchange
Commission within 120 days after the year covered by this Form 10-KSB with
respect to its Annual Meeting of Shareholders to be held on May 25, 2006.
ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.
Incorporated herein by reference to Rockwell Medical Technologies, Inc.
definitive proxy statement to be filed with the Securities and Exchange
Commission within 120 days after the year covered by this Form 10-KSB with
respect to its Annual Meeting of Shareholders to be held on May 25, 2006.
ITEMS 13. EXHIBITS.
(a) Exhibits
3(i).1 Articles of Incorporation of the Company, incorporated by reference
to Exhibit 3(i).1 to the Company's Registration Statement on Form
SB-2, File No. 333-31991.
3(i).2 Certificate of Amendment to Articles of Incorporation of the
Company, incorporated by reference to Exhibit 3(i).2 to the
Company's Registration Statement on Form SB-2, File No. 333-31991.
3(i).3 Certificate of Correction to Articles of Incorporation of the
Company, incorporated by reference to Exhibit 3(i).3 to the
Company's Registration Statement on Form SB-2, File No. 333-31991.
3(i).4 Certificate of Amendment to Articles of Incorporation of the
Company, incorporated by reference to Exhibit 3(i).4 to the
Company's Registration Statement on Form SB-2, File No. 333-31991.
3(ii) Bylaws of the Company, incorporated by reference to Exhibit 3(ii)
to the Company's Registration Statement on Form SB-2, File No. 333-
31991.
10.1 Rockwell Medical Technologies, Inc. 1997 Stock Option Plan,
incorporated by reference to the Proxy Statement for the Annual
Meeting of Shareholders filed on April 21, 2005.
10.2 Lease Agreement dated March 12, 2000 between the Company and DFW
Trade Center III Limited Partnership incorporated by reference to
the annual report on Form 10-KSB filed March 30, 2000.
10.3 Lease Agreement dated October 23, 2000 between the Company and
International-Wixom, LLC I ncorporated by reference to the
quarterly report on Form 10-QSB filed November 14, 2000.
10.4 Licensing Agreement between the Company and Ash Medical Systems,
Inc. dated October 3, 2001 with certain portions of the exhibit
deleted under a request for confidential treatment under rule 24b-
2of the Securities Act of 1934 incorporated by reference to the
annual report on form 10-KSB filed April 1, 2002.
21
10.5 Licensing Agreement between the Company and Charak LLC and Dr. Ajay
Gupta dated January 7, 2002 with certain portions of the exhibit
deleted under a request for confidential treatment under rule 24b-
2of the Securities Act of 1934 incorporated by reference to the
annual report on Form 10-KSB filed April 1, 2002.
10.6 Supply Agreement between the Company and DaVita, Inc. dated March
7, 2003 with certain portions of the exhibit deleted under a
request for confidential treatment under rule 24b-2 of the
Securities Act of 1934 incorporated by reference to the annual
report on Form 10-KSB filed March 28, 2003.
10.8 Supply Agreement between the Company and DaVita, Inc. dated May 5,
2004 with certain portions of the exhibit deleted under a request
for confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934 incorporated by reference to the quarterly
report on Form 10-QSB filed on May 17, 2004.
10.9 Loan and Security Agreement dated as of March 29, 2005 between the
Company and Standard Federal Bank National Association incorporated
by reference to the annual report on Form 10-KSB filed March 31,
2005.
10.10 Revolving Note dated as of March 29, 2005 executed by the Company
for the benefit of Standard Federal Bank National Association
incorporated by reference to the annual report on Form 10-KSB filed
March 31, 2005.
10.11 Unconditional Guaranty dated as of March 29, 2005 executed by
Rockwell Transportation, Inc. for the benefit of Standard Federal
Bank National Association incorporated by reference to the annual
report on Form 10-KSB filed March 31, 2005.
10.12 Second Amendment of Industrial Lease Agreement between Rockwell
Medical Technologies, Inc. and DCT DFW, LP dated August 17, 2005,
incorporated by reference to Exhibit 99.1 on Form 8-K filed on
August 19, 2005.
10.13 Amending Agreement made the 16th day of January, 2006, by and
between Dr. Ajay Gupta, Charak LLC and Rockwell Medical
Technologies, Inc.
14.1 Rockwell Medical Technologies, Inc. Code of Ethics incorporated by
reference to the Definitive Proxy Statement for our 2004 Annual
Meeting of Shareholders filed April 23,2004.
21.1 List of Subsidiaries incorporated by reference to Exhibit 21.1 to
the Company's Registration Statement on Form SB-2, File No. 333-
31991.
23.1 Consent of Plante & Moran, PLLC.
31.1 Certifications of Chief Executive Officer Pursuant to Rule 13a-
14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act
of 2002.
31.2 Certifications of Chief Financial Officer Pursuant to Rule 13a-
14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act
of 2002.
32.1 Certifications of the Chief Executive Officer and Chief Financial
Officer, Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
Incorporated herein by reference to Rockwell Medical Technologies, Inc.
definitive proxy statement to be filed with the Securities and Exchange
Commission within 120 days after the year covered by this Form 10-KSB with
respect to its Annual Meeting of Shareholders to be held on May 25, 2006.
22
SIGNATURES
In accordance with Section 13 or 15(d) of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereto duly
authorized.
ROCKWELL MEDICAL TECHNOLOGIES, INC.
(Registrant)
By: /s/ ROBERT L. CHIOINI
------------------------------------
Robert L. Chioini
President and Chief Executive
Officer
In accordance with Section 13 or 15(d) of the Exchange Act, this report has
been signed by the following persons in the capacities and on the dates
indicated.
SIGNATURE TITLE DATE
--------- ----- ----
/s/ ROBERT L. CHIOINI President, Chief Executive Officer March 21, 2006
------------------------------- and Director (Principal Executive
Robert L. Chioini Officer)
/s/ THOMAS E. KLEMA Vice President of Finance, Chief March 21, 2006
------------------------------- Financial Officer, Treasurer and
Thomas E. Klema Secretary (Principal Financial
Officer and Principal Accounting
Officer)
/s/ KENNETH L. HOLT Director March 21, 2006
-------------------------------
Kenneth L. Holt
/s/ RONALD D. BOYD Director March 21, 2006
-------------------------------
Ronald D. Boyd
/s/ PATRICK J. BAGLEY Director March 21, 2006
-------------------------------
Patrick J. Bagley
23
INDEX TO FINANCIAL STATEMENTS
PAGE
----------
I. Consolidated Financial Statements for Rockwell Medical
Technologies, Inc. and Subsidiary
Report of Independent Registered Accounting Firm for the years
ended December 31, 2005 and 2004............................. F-1
Consolidated Balance Sheets at December 31, 2005 and December
31, 2004..................................................... F-2
Consolidated Income Statement for the years ended December 31,
2005 and 2004................................................ F-3
Consolidated Statement of Changes in Shareholders' Equity for
the years ended December 31, 2005 and 2004................... F-4
Consolidated Statements of Cash Flow for the years ended
December 31, 2005 and 2004................................... F-5
Notes to the Consolidated Financial Statements................. F-6 - F-16
PLANTE & MORAN, PLLC LETTERHEAD
REPORT OF INDEPENDENT REGISTERED ACCOUNTING FIRM
To the Board of Directors and Shareholders
Rockwell Medical Technologies, Inc. and Subsidiary
We have audited the consolidated balance sheet of Rockwell Medical
Technologies, Inc. and Subsidiary as of December 31, 2005 and 2004 and the
related consolidated statements of income, shareholders' equity, and cash flows
for the years then ended. These financial statements are the responsibility of
the Company's management. Our responsibility is to express an opinion on these
financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public
Company Accounting Oversight Board (United States). Those standards require that
we plan and perform the audits to obtain reasonable assurance about whether the
financial statements are free of material misstatement. Rockwell Medical
Technologies, Inc. and Subsidiary is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting.
Accordingly, we express no such opinion. An audit includes examining, on a test
basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above,
present fairly, in all material respects, the financial position of Rockwell
Medical Technologies, Inc. and Subsidiary as of December 31, 2005 and 2004, and
the results of their operations and their cash flows for the years then ended,
in conformity with accounting principles generally accepted in the United States
of America.
Plante & Moran, PLLC
Auburn Hills, Michigan
March 16, 2006
F-1
ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
AS OF DECEMBER 31, 2005 AND 2004
(WHOLE DOLLARS)
DECEMBER 31, DECEMBER 31,
2005 2004
------------ ------------
ASSETS
Cash and Cash Equivalents................................ $ 299,031 $ 166,195
Restricted Cash Equivalents.............................. -- 8,662
Accounts Receivable, net of a reserve of $70,000 in 2005
and $44,500 in 2004.................................... 2,836,072 2,302,093
Inventory................................................ 2,051,819 1,652,457
Other Current Assets..................................... 193,158 111,630
------------ -----------
Total Current Assets................................ 5,380,080 4,241,037
Property and Equipment, net.............................. 2,430,222 2,048,665
Intangible Assets........................................ 394,819 369,508
Goodwill................................................. 920,745 920,745
Other Non-current Assets................................. 134,794 120,597
------------ -----------
Total Assets........................................ $ 9,260,660 $ 7,700,552
============ ===========
LIABILITIES AND SHAREHOLDERS' EQUITY
Short Term Borrowings.................................... $ 1,800,000 $ 452,682
Notes Payable & Capitalized Lease Obligations............ 522,439 389,602
Accounts Payable......................................... 1,795,393 2,124,679
Accrued Liabilities...................................... 530,749 481,587
Customer Deposits........................................ 33,558 11,005
------------ -----------
Total Current Liabilities........................... 4,682,139 3,459,555
Long Term Notes Payable & Capitalized Lease Obligations.. 733,723 818,678
Shareholders' Equity:
Common Shares, no par value, 8,886,948 and 8,556,531
shares issued and outstanding.......................... 12,628,539 11,870,909
Common Share Purchase Warrants, 3,591,385 and 3,761,071
shares issued and outstanding.......................... 1,414,876 320,150
Accumulated Deficit...................................... (10,198,617) (8,768,740)
------------ -----------
Total Shareholders' Equity.......................... 3,844,798 3,422,319
------------ -----------
Total Liabilities And Shareholders' Equity.......... $ 9,260,660 $ 7,700,552
============ ===========
The accompanying notes are an integral part of the consolidated financial
statements.
F-2
ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY
CONSOLIDATED INCOME STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004
(WHOLE DOLLARS)
2005 2004
----------- -----------
Sales.............................................. $27,694,955 $17,944,710
Cost of Sales...................................... 24,689,912 15,139,215
----------- -----------
Gross Profit..................................... 3,005,043 2,805,495
Selling, General and Administrative................ 2,867,608 2,396,315
----------- -----------
Operating Income................................. 137,435 409,180
Other Income....................................... 137,468 --
Interest Expense, net.............................. 198,095 197,658
----------- -----------
Income Before Income Taxes....................... 76,808 211,522
Income Tax Expense................................. -- --
----------- -----------
Net Income....................................... $ 76,808 $ 211,522
=========== ===========
Basic And Diluted Earnings Per Share............... $ .01 $ .02
The accompanying notes are an integral part of the consolidated financial
statements.
F-3
ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004
(WHOLE DOLLARS)
COMMON SHARES PURCHASE WARRANTS TOTAL
---------------------- --------------------- ACCUMULATED SHAREHOLDERS'
SHARES AMOUNT WARRANTS AMOUNT DEFICIT EQUITY
--------- ----------- --------- ---------- ------------ -------------
Balance as of December 31,
2003..................... 8,519,405 $11,832,220 3,766,071 $ 320,150 $ (8,980,262) $3,172,108
Issuance of Common Shares.. 32,126 34,989 -- -- -- 34,989
Exercise of Purchase
Warrants................. 5,000 3,700 (5,000) -- -- 3,700
Net Income................. 211,522 211,522
--------- ----------- --------- ---------- ------------ ----------
Balance as of December 31,
2004..................... 8,556,531 $11,870,909 3,761,071 $ 320,150 $ (8,768,740) $3,422,319
Issuance of Common Shares.. 167,881 336,849 -- -- -- 336,849
Exercise of Purchase
Warrants................. 162,536 420,781 (162,536) (80,630) -- 340,151
Expiration of Warrants..... -- -- (7,150) -- -- --
Warrant Exchange........... -- -- -- 1,175,356 (1,506,685) (331,329)
Net Income................. -- -- -- -- 76,808 76,808
--------- ----------- --------- ---------- ------------ ----------
Balance as of December 31,
2005..................... 8,869,481 $12,628,539 3,591,385 $1,414,876 $(10,198,617) $3,844,798
========= =========== ========= ========== ============ ==========
The accompanying notes are an integral part of the consolidated financial
statements.
F-4
ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004
(WHOLE DOLLARS)
2005 2004
----------- ------------
Cash Flows From Operating Activities:
Net Income............................................. $ 76,808 $ 211,522
Adjustments To Reconcile Net Income To Net Cash Used In
Operating Activities:
Depreciation and Amortization....................... 716,312 629,697
Changes in Assets and Liabilities:
(Increase) in Accounts Receivable................. (533,979) (132,529)
(Increase) in Inventory........................... (399,362) (302,166)
(Increase) in Other Assets........................ (95,725) (789)
Increase (Decrease) in Accounts Payable........... (329,286) 457,727
Increase (Decrease) in Other Liabilities.......... 71,715 163,073
----------- ------------
Changes in Assets and Liabilities.............. (1,286,637) 185,316
----------- ------------
Cash Provided (Used) By Operating Activities... (493,517) 1,026,535
Cash Flows From Investing Activities:
Purchase of Equipment.................................. (576,450) (392,046)
(Increase) Decrease in Restricted Cash Equivalents..... 8,662 --
Purchase of Intangible Assets.......................... (59,924) (83,095)
----------- ------------
Cash Provided (Used) By Investing Activities... (627,712) (475,141)
Cash Flows From Financing Activities:
Proceeds From Borrowings on Line of Credit............. 5,937,395 16,794,439
Payments on Line of Credit............................. (4,590,077) (16,983,775)
Issuance of Common Shares and Purchase Warrants........ 345,671 38,689
Payments on Notes Payable.............................. (438,924) (341,191)
----------- ------------
Cash Provided (Used) By Financing Activities... 1,254,065 (491,838)
Increase In Cash......................................... 132,836 59,556
Cash At Beginning Of Period.............................. 166,195 106,639
----------- ------------
Cash At End Of Period.................................... $ 299,031 $ 166,195
=========== ============
Supplemental Cash Flow disclosure:
2005 2004
-------- --------
Interest Paid........................................... $198,192 $197,818
The accompanying notes are an integral part of the consolidated financial
statements.
F-5
ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. DESCRIPTION OF BUSINESS
We manufacture, sell and distribute hemodialysis concentrates and other
ancillary medical products and supplies used in the treatment of patients with
End Stage Renal Disease "ESRD". We supply our products to medical service
providers who treat patients with kidney disease. Our products are used to
cleanse patients' blood and replace nutrients lost during the kidney dialysis
process. We primarily sell our products in the United States.
We are regulated by the Federal Food and Drug Administration under the
Federal Drug and Cosmetics Act, as well as by other federal, state and local
agencies. We have received 510(k) approval from the FDA to market hemodialysis
solutions and powders. We also have 510(k) approval to sell our Dri-Sate Dry
Acid Concentrate product line and our Dri-Sate Mixer.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
BASIS OF PRESENTATION
Our consolidated financial statements include our accounts and the accounts
for our wholly owned subsidiary, Rockwell Transportation, Inc.
All intercompany balances and transactions have been eliminated.
REVENUE RECOGNITION
We recognize revenue at the time we transfer title to our products to our
customers consistent with generally accepted accounting principles. Generally,
we recognize revenue when our products are delivered to our customer's location
consistent with our terms of sale. In most instances title for goods shipped
internationally transfers to the buyer once it leaves our facility and
therefore, we recognize revenue upon shipment to foreign customers.
SHIPPING AND HANDLING REVENUE AND COSTS
Our products are generally priced on a delivered basis with the price of
delivery included in the overall price of our products which is reported as
sales. Separately identified freight and handling charges are also included in
sales. Our trucks which deliver our products to our customers sometimes generate
backhaul revenue from hauling freight for other third parties. Revenue from
backhaul activity is recognized upon completion of the delivery service.
We include shipping and handling costs including expenses of Rockwell
Transportation, Inc. in cost of sales.
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH
We consider cash on hand, unrestricted certificates of deposit and short
term marketable securities as cash and cash equivalents.
ACCOUNTS RECEIVABLE
Accounts receivable are stated at invoice amounts. The carrying amount of
trade accounts receivable is reduced by an allowance for doubtful accounts that
reflects our best estimate of accounts that may not be collected. We review
outstanding trade account receivable balances and based on our assessment of
expected collections, we estimate the portion, if any, of the balance that may
not be collected as well as a general valuation allowance for other accounts
receivable based primarily based on historical experience. All accounts or
portions thereof deemed to be uncollectible are written off to the allowance for
doubtful accounts.
INVENTORY
Inventory is stated at the lower of cost or net realizable value. Cost is
determined on the first-in first-out (FIFO) method.
F-6
ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
PROPERTY AND EQUIPMENT
Property and equipment are recorded at cost. Expenditures for normal
maintenance and repairs are charged to expense as incurred. Property and
equipment are depreciated using the straight-line method over their useful
lives, which range from three to ten years. Leasehold improvements are amortized
using the straight-line method over the shorter of their useful lives or the
related lease term.
LICENSING FEES
License fees related to the technology, intellectual property and marketing
rights for dialysate iron covered under certain issued patents have been
capitalized and are being amortized over the life of the related patents which
is generally 17 years.
GOODWILL, INTANGIBLE ASSETS AND LONG LIVED ASSETS
The recorded amounts of goodwill and other intangibles from prior business
combinations are based on management's best estimates of the fair values of
assets acquired and liabilities assumed at the date of acquisition. Goodwill is
not amortized; however, it must be tested for impairment at least annually.
Amortization continues to be recorded for other intangible assets with definite
lives over their estimated useful lives. Intangible assets subject to
amortization are reviewed for potential impairment whenever events or
circumstances indicate that carrying amounts may not be recoverable.
An impairment review of goodwill, intangible assets, and property and
equipment is performed annually or whenever a change in condition occurs which
indicates that the carrying amounts of assets may not be recoverable. Such
changes may include changes in our business strategies and plans, changes to our
customer contracts, changes to our product lines and changes in our operating
practices. We use a variety of factors to assess the realizable value of long-
lived assets depending on their nature and use.
The useful lives of other intangible assets are based on management's best
estimates of the period over which the assets are expected to contribute
directly or indirectly to our future cash flows. Management annually evaluates
the remaining useful lives of intangible assets with finite useful lives to
determine whether events and circumstances warrant a revision to the remaining
amortization periods. It is reasonably possible that management's estimates of
the carrying amount of goodwill and the remaining useful lives of other
intangible assets may change in the near term.
INCOME TAXES
A current tax liability or asset is recognized for the estimated taxes
payable or refundable on tax returns for the year. Deferred tax liabilities or
assets are recognized for the estimated future tax effects of temporary
differences between book and tax accounting and operating loss and tax credit
carryforwards.
PRODUCT DEVELOPMENT AND RESEARCH
We incurred product development and research costs related to the
commercial development, patent approval and regulatory approval of new products,
including iron supplemented dialysate, aggregating approximately $350,000 and
$200,000 in 2005 and 2004, respectively.
OTHER INCOME
We were the plaintiff in certain litigation that was settled in the first
quarter of 2005. We realized the full proceeds of the settlement which totaled
$241,000 and we recognized $137,468 of other income from this settlement in the
first quarter of 2005. A portion of the cash received was from the exercise of
stock options by the defendant during the first quarter of 2005 which totaled
$103,750.
F-7
ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
STOCK OPTIONS
Stock options granted to employees are accounted for using the intrinsic
value method in accordance with Accounting Principles Board Opinion No. 25
Accounting for Stock Issued to Employees, as allowed under SFAS No. 123
Accounting for Stock-Based Compensation. Stock option grants to employees do not
result in an expense if the exercise price is at least equal to the market price
at the date of grant. Exercise prices on all options granted equal or exceed the
fair market value of the underlying stock at the applicable grant dates and,
accordingly, no compensation cost is recorded in the accompanying financial
statements as a result of stock options awarded under the plan to employees.
Stock options granted to non-employees are recorded at the fair value of the
awards at the date of the grant using the Black-Scholes model.
Our reported and pro forma information for the years ended December 31:
2005 2004
----------- ---------
As reported net income available to common
shareholders....................................... $ 76,808 $ 211,522
Less: Stock based compensation expense determined
under the fair market value method, net of tax..... 2,427,257 879,457
----------- ---------
Pro forma net income (loss).......................... $(2,350,449) $(667,935)
=========== =========
As reported basic earnings per share and diluted
earnings per share................................. $ .01 $ .02
Pro forma earnings (loss) per share and diluted
earnings (loss) per share.......................... $ (0.27) $ (0.08)
NET EARNINGS PER SHARE
We computed our basic earnings (loss) per share using weighted average
shares outstanding for each respective period. Diluted earnings per share also
reflect the weighted average impact from the date of issuance of all potentially
dilutive securities, consisting of stock options and common share purchase
warrants, unless inclusion would have had an antidilutive effect. Actual
weighted average shares outstanding used in calculating basic and diluted
earnings per share were:
2005 2004
--------- ---------
Basic Weighted Average Shares Outstanding............. 8,674,651 8,546,302
Effect of Dilutive Securities......................... 682,239 758,821
--------- ---------
Diluted Weighted Average Shares Outstanding........... 9,356,990 9,305,123
========= =========
At December 31, 2005 potentially dilutive securities comprised 3,359,335
stock options exercisable at prices from $.55 to $4.55 per share, 3,211,688
common share purchase warrants exercisable at $3.90 per common share, 354,697
common share purchase warrants exercisable at $4.50 per common share and 25,000
common share purchase warrants exercisable at $2.50 per common share.
At December 31, 2004 potentially dilutive securities comprised 2,707,717
stock options exercisable at prices from $.55 to $4.05 per share, 3,625,000
common share purchase warrants exercisable at $4.50 per common share and 136,071
common share purchase warrants exercisable at various prices ranging from $.50
to $4.05.
ESTIMATES IN PREPARATION OF FINANCIAL STATEMENTS
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make certain estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and reported amounts of revenues and expenses during the period.
Actual results could differ from those estimates.
F-8
ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
3. MANAGEMENT'S PLAN OF OPERATION
Our strategy includes expanding our operations and seeking FDA approval for
our iron supplemented dialysate product. We believe that we can continue to grow
and expand our business. We plan to develop and offer new and innovative
products to the dialysis market. We expect that we will continue to realize
substantial sales growth in the future. In 2005, our revenue increased by
$9,750,245 or 54.3% over 2004.
In January of 2006, prior to expiration of common share purchase warrants
we issued in November of 2005 ("New Warrants") in exchange for most of our
previously outstanding common share purchase warrants, most of the holders of
such New Warrants exercised the New Warrants from which we realized gross
proceeds of $9.3 million. We believe these proceeds will fund all of our
foreseeable cash requirements in 2006.
We have two major areas of strategic focus in our business. First, we plan
to develop our dialysis concentrate solutions and ancillary supply business.
Second, we plan to expand our product offering to include drugs and vitamins
administered to dialysis patients.
Our plan is to expand our operations to serve dialysis providers throughout
the United States and internationally on an export basis. We anticipate that, as
a result of our existing supply agreements, our customer relationships and our
changing market dynamics, we have the opportunity to capture substantial market
share that will lead to sustaining and increasing our profitable operations. We
expect that we will continue to realize substantial growth during 2006 and that
we will require additional working capital and capital expenditures to fund this
growth. In order to fund facility expansions and certain capital expenditures,
we intend to enter into lease financing arrangements. We anticipate that our
working capital line of $2.75 million is sufficient to meet our requirements for
working capital expansion in the year ahead.
The dialysis provider industry that we serve is becoming increasingly
concentrated. As a result, our business is predominantly with national and
regional dialysis chains. If we were to lose a significant portion of our
business with major national and regional dialysis chains, it could have a
substantial negative impact on our cash flow and results. If we were to lose a
substantial portion of our business, it may have a detrimental impact on our
ability to continue our operations in their current form or to continue to
execute our business strategy. If we lost a substantial portion of our business,
we would be required to take actions to conserve our cash resources and to
mitigate the impact of any such losses on our business operations.
Our second major area of focus is to expand our product offering to include
drugs and vitamins administered to dialysis patients using our dialysis
concentrate solutions as the delivery method. We are seeking FDA approval for
our dialysate iron drug product. The development and approval of drugs can be
expensive and take a long time. Drug development and approval costs may offset
some or all of any earnings during the approval process and we may incur losses
in the future. We estimate the cash required to fund development and approval of
our new iron supplemented dialysate product will be between
$6,000,000 -- $8,000,000 over the next several years. We expect to spend between
$3,000,000 -$4,000,000 in 2006 on product testing and possibly more depending on
the progress of testing during the year.
To fund our business development efforts for our two key areas of focus we
completed an equity offering of our common shares under which our publicly
traded warrants were exercised for common shares. We issued 2,401,021 Common
shares at $3.90 per common shares resulting in gross proceeds of $9,363,000 with
$9,135,000 raised in January 2006. These substantial cash resources are intended
to be used for our business development initiatives. We anticipate that the net
proceeds from this offering will be sufficient for us to complete the FDA
approval process for our dialysate iron product. However, there is no guarantee
that we will not require additional funds to execute our strategy or pursue
other business development opportunities. If we need additional funds in the
future, we will evaluate both debt and equity financing as potential sources of
funds.
F-9
ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
4. SIGNIFICANT MARKET SEGMENTS
We operate in one market segment which involves the manufacture and
distribution of hemodialysis concentrates, dialysis kits and ancillary products
used in the dialysis process to hemodialysis clinics. For the year ended
December 31, 2005, two customers each accounted for more than 10% of our total
sales, representing 55% of total sales. For the year ended December 31, 2004,
two customers each accounted for more than 10% of our total sales, representing
52% of total sales. Our accounts receivable from these customers were $840,000
and $1,362,000 as of December 31, 2005 and 2004, respectively. We are dependent
on these customers and the loss of any of them would have a material adverse
effect on our business, financial condition and results of operations. Our
international sales including products sold to domestic distributors that are
delivered internationally aggregated 28% and 4% of overall sales in 2005 and
2004, respectively.
5. INVENTORY
Components of inventory as of December 31, 2005 and 2004 are as follows:
2005 2004
---------- ----------
Raw Materials........................................ $ 509,248 $ 399,455
Finished Goods....................................... 1,542,571 1,253,002
---------- ----------
Total........................................... $2,051,819 $1,652,457
========== ==========
6. PROPERTY AND EQUIPMENT
Major classes of Property and Equipment, stated at cost, as of December 31,
2005 and 2004 are as follows:
2005 2004
----------- -----------
Leasehold Improvements.............................. $ 447,207 $ 380,319
Machinery and Equipment............................. 3,326,552 2,652,899
Office Equipment and Furniture...................... 308,992 247,582
Laboratory Equipment................................ 298,510 236,747
Transportation Equipment............................ 904,862 705,320
----------- -----------
5,286,123 4,222.867
Accumulated Depreciation.......................... (2,855,901) (2,174,202)
----------- -----------
Net Property and Equipment.......................... $ 2,430,222 $ 2,048,665
=========== ===========
Included in the table above are assets under capital lease obligations with
a cost of $1,256,186 and $873,628 and a net book value of $901,698 and $669,514,
as of December 31, 2005 and 2004, respectively.
Depreciation expense was $681,699 for 2005 and $602,039 for 2004.
7. GOODWILL AND INTANGIBLE ASSETS
Total goodwill was $920,745 at December 31, 2005 and 2004. We completed our
annual impairment tests as of November 30, 2005 and 2004 and determined that no
adjustment for impairment of goodwill was required.
We entered into a global licensing agreement in 2001 covering patents for a
method for iron delivery to a patient by transfer from dialysate. The invention
relates to methods and compositions for delivering iron to an iron-deficient
patient using an iron complex in an aqueous solution. We entered into a second
licensing agreement in 2002 covering patents for a more specific form of iron
which may be delivered via dialysate. We intend to obtain FDA approval for this
product as a drug additive to our dialysate product line which upon approval
will be marketed as an iron maintenance therapy for dialysis patients.
F-10
ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
We have capitalized the licensing fees paid for the rights to use this
patented technology as an intangible asset. As of December 31, 2005, we have
capitalized licensing fees of $510,138, net of accumulated amortization of
$115,319. As of December 31, 2004, we have capitalized licensing fees of
$450,214, net of accumulated amortization of $80,705. Our policy is to amortize
licensing fees over the life of the patents pertaining to the licensing
agreements. We recognized amortization expense of $34,614 in 2005 and $27,658 in
2004. Estimated amortization expense for licensing fees for 2005 through 2009 is
approximately $37,000 per year. One of the licensing agreements requires
additional payments upon achievement of certain milestones.
8. LINE OF CREDIT
On March 29, 2005, we entered into a new line of credit with a financial
institution. The loan agreement provides for revolving borrowings of up to
$2,750,000. We are permitted to borrow up to 80% of eligible accounts receivable
and 40% of eligible inventory up to $600,000. Borrowings under the loan
agreement are secured by accounts receivable, inventory and certain other
assets. The annual interest rate payable on revolving borrowings under the loan
agreement is the lender's prime rate plus 75 basis points. The lender's
commitment to make revolving borrowings under the loan agreement expires on
March 31, 2006. As of December 31, 2005, we had borrowed $1,800,000 under this
line of credit.
We had a two year revolving credit line facility with a financial
institution which expired March 29, 2005 and was replaced by the credit facility
noted above. The expired credit facility had a $2,500,000 borrowing limit which
was secured by our accounts receivable and other assets. Borrowings under that
facility were limited to 80% of eligible accounts receivable. We were obligated
to pay interest at the rate of two percentage points over the prime rate, plus
other fees aggregating .25% of the loan balance.
9. NOTES PAYABLE & CAPITAL LEASE OBLIGATIONS
NOTES PAYABLE
In August 2001, we entered into a financing agreement with a financial
institution to fund $1,000,000 of equipment capital expenditures for our
manufacturing facilities. The note payable requires monthly payments of
principal and interest aggregating $20,884 through June 2007. The note had a
balance of $351,379 and $561,637 at December 31, 2005 and 2004, respectively.
The note bears interest at a fixed rate of 8.65% and is collateralized by the
equipment acquired by the Company.
Future principal payments on notes payable are:
Year ending December 31, 2006.................................. $229,173
Year ending December 31, 2007.................................. 122,206
--------
Total Notes Payable.......................................... $351,379
========
CAPITAL LEASE OBLIGATIONS
We entered into capital lease obligations primarily related to equipment
with a fair market value aggregating $486,806 and $315,282 for the years ending
December 31, 2005 and 2004, respectively. In addition, we have other capital
lease obligations related to financing other equipment. These capital lease
obligations require even monthly installments over periods ranging from 2006-
2010 and interest rates on the leases range from 5%-17.0%. These obligations
under capital leases had outstanding balances of $904,783 and $646,643 at
December 31, 2005 and 2004, respectively.
F-11
ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
Future minimum lease payments under capital lease obligations are:
Year ending December 31, 2006................................. $ 379,865
Year ending December 31, 2007................................. 314,181
Year ending December 31, 2008................................. 214,960
Year ending December 31, 2009................................. 176,850
Year ending December 31, 2010................................. 5,159
----------
Total minimum payments on capital lease obligations......... 1,091,015
Interest...................................................... (186,232)
----------
Present value of minimum lease payments..................... 904,783
Current portion of capital lease obligations.................. (293,266)
----------
Long-term capital lease obligations......................... $ 611,517
==========
11. OPERATING LEASES
We lease our production facilities and administrative offices as well as
certain equipment used in our operations. The lease terms range from monthly to
seven years. Lease payments under all operating leases were $1,058,004 and
$812,216 for the years ended December 31, 2005 and 2004, respectively.
We have long term leases on two buildings that are approximately 51,000
square feet each and that expire in July 2008 and August 2010, respectively. We
also have a monthly lease on a building that is approximately 60,000 square
feet.
Future minimum rental payments under these lease agreements are as follows:
Year ending December 31, 2006................................. $ 843,666
Year ending December 31, 2007................................. 778,441
Year ending December 31, 2008................................. 517,068
Year ending December 31, 2009................................. 373,198
Year ending December 31, 2010................................. 198,259
----------
Total....................................................... $2,710,633
==========
12. INCOME TAXES
We recognized no income tax expense or benefit for the years ended December
31, 2005 and 2004. We earned a profit in both years and retained a valuation
allowance against our net deferred tax assets due to our limited history of
taxable income coupled with anticipated future spending on our product
development plans which may offset some or all of our income.
A reconciliation of income tax expense at the statutory rate to income tax
expense at our effective tax rate is as follows:
2005 2004
-------- --------
Tax Expense Computed at 34% of Pretax Income........... $ 26,000 $ 72,000
Effect of Permanent Differences Principally Related
to Non-deductible expenses........................ -- --
Effect of Change in Valuation Allowance.............. (26,000) (72,000)
-------- --------
Total Income Tax Benefit............................. $ -0- $ -0-
======== ========
F-12
ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
The details of the net deferred tax asset are as follows:
2005 2004
----------- -----------
Total Deferred Tax Assets........................... $ 2,908,000 $ 2,721,400
Total Deferred Tax Liabilities...................... (257,600) (45,000)
Valuation Allowance Recognized for Deferred Tax
Assets............................................ (2,650,400) (2,676,400)
----------- -----------
Net Deferred Tax Asset.............................. $ -0- $ -0-
=========== ===========
Deferred income tax liabilities result primarily from the use of
accelerated depreciation for tax reporting purposes. Deferred income tax assets
result primarily from net operating loss carryforwards. For tax purposes, we
have net operating loss carryforwards of approximately $8,300,000 that expire
between 2012 and 2024.
In assessing the realizability of deferred tax assets, management considers
whether it is more likely than not that some portion or all of the deferred tax
assets will be realized upon the generation of future taxable income during the
periods in which those temporary differences become deductible. Due to
anticipated spending on research and development over the next several years,
coupled with our limited history of operating income, management has placed a
full valuation allowance against the net deferred tax assets as of December 31,
2005 and 2004.
13. CAPITAL STOCK
Our authorized capital stock consists of 20,000,000 common shares, no par
value per share, of which 8,886,948 shares were outstanding at December 31, 2005
and 8,556,531 shares were outstanding at December 31, 2004; 2,000,000 preferred
shares, none issued or outstanding, and 1,416,664 of 8.5% non-voting cumulative
redeemable Series A Preferred Shares, $1.00 par value, of which none were
outstanding at either December 31, 2005 or December 31, 2004.
During 2005, we issued 167,881 common shares as a result of the exercise of
stock options by employees and realized proceeds of $336,849 or $2.01 per share
on average. We also issued 103,921 common shares upon the exercise of warrants
to investors in our private placement ("Private Warrants," as defined below). We
realized proceeds of $111,554 or $1.07 per share on average. Investors
exercising these private placement warrants received unregistered common shares
which may not be resold for a period of one year following the date they were
acquired. We also issued 58,615 freely trading common shares upon the exercise
of publicly traded warrants ("Public Warrants," as defined below). We realized
$228,599 or $3.90 per share in gross proceeds from these exercises.
During 2004, we issued 32,126 common shares as a result of the exercise of
stock options by employees and realized proceeds of $34,989 or $1.09 per share
on average. We also issued 5,000 common shares upon the exercise of warrants to
investors in our private placement. We realized proceeds of $3,700 or $.74 per
share on average. Investors exercising these private placement warrants received
unregistered common shares which may not be resold for a period of one year
following the date they were acquired.
COMMON SHARES
Holders of the common shares are entitled to one vote per share on all
matters submitted to a vote of our shareholders and are to receive dividends
when and if declared by the Board of Directors. The Board is authorized to issue
additional common shares within the limits of the Company's Articles of
Incorporation without further shareholder action.
F-13
ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
WARRANTS
We have both publicly traded common share purchase warrants ("Public
Warrants") issued in 1998 and common share purchase warrants ("Private
Warrants") issued in conjunction with a private placement of our common shares
in 2002 and other investment banking activities.
Holders of the Public Warrants, were entitled to purchase one common share
at the exercise price of $4.50 per share for a period of three years commencing
January 26, 1999 and expiring January 26, 2002. The Board of Directors approved
extending the expiration date of these warrants until January 26, 2006 under the
same terms and conditions. There were 3,625,000 Public Warrants issued and
outstanding at December 31, 2004.
On July 29, 2005, we filed with the Securities and Exchange Commission (the
"SEC") a registration statement on Forms S-4 and SB-2 (the "Registration
Statement") with respect to an offer to exchange new common share purchase
warrants expiring January 26, 2006 with an exercise price of $3.90 ("New
Warrants") for each of the 3,625,000 currently outstanding common share purchase
warrants expiring January 26, 2006 with an exercise price of $4.50 per share
("Old Warrants"). The SEC declared the Registration Statement effective on
October 20, 2005.
On November 28, 2005, we completed this exchange which allowed the warrant
holders to exchange their Old Warrant with an exercise price of $4.50 per share
for a New Warrant with an exercise price of $3.90 per share. All other terms and
conditions, including expiration, remained the same. There were 354,697 Old
Warrants that were not tendered for exchange and remained outstanding as of
December 31, 2005. All of the Old Warrants expired unexercised at January 26,
2006.
We issued 3,270,303 New Warrants in the warrant exchange. During 2005,
58,615 of New Warrants were exercised and we realized $228,599 in gross proceeds
from these warrant exercises. As of December 31, 2005, 3,211,688 of the New
Warrants remained outstanding. See Note 17.
Holders of the Private Warrants issued in conjunction with subscriptions to
private placement offerings of common shares in 2002 were entitled to purchase
one common share at a stated price. The Private Warrants had a three year term
expiring between May 2005 and October 2005. The common shares underlying these
Private Warrants have not been registered. Investors that exercised these
Private Warrants received unregistered common shares which may not be resold for
a period of one year following the date they are acquired. In 2003, we issued
25,000 Private Warrants to an investment banker with an exercise price of $2.50
per common share which expire during 2006. In 2002, we issued 128,460 Private
Warrants to investors and investment bankers with exercise prices ranging from
$.50 per common share to $2.70 per common share.
14. STOCK OPTIONS
EMPLOYEE STOCK OPTIONS
The Board of Directors approved the Rockwell Medical Technologies, Inc.,
1997 Stock Option Plan on July 15, 1997 (the "Plan"). The Stock Option Committee
as appointed by the Board of Directors administers the Plan, which provides for
grants of nonqualified or incentive stock options to key employees, officers,
directors, consultants and advisors to the Company. Currently the Stock Option
Committee consists of our entire Board of Directors. On May 26, 2005, our
shareholders adopted an amendment to the stock option plan to increase the
number of options available to be granted to 4,500,000 from 3,900,000. Exercise
prices, subject to certain plan limitations, are at the discretion of the Stock
Option Committee of the Board of Directors. Options granted normally expire 10
years from the date of grant or upon termination of employment. The Stock Option
Committee of the Board of Directors determines vesting rights on the date of
grant. Employee options typically vest over a three year period from the date of
grant. The Board of Directors accelerated the vesting rights to all unvested
current and prior option grants such that they all became vested effective as of
December 31, 2005.
F-14
ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
A summary of the status of the Company's Employee Stock Option Plan
excluding options granted to consultants is as follows:
SHARES PRICE
--------- -----
Outstanding at December 31, 2003......................... 1,918,927 1.51
Granted................................................ 858,000 3.17
Exercised.............................................. (32,126) 1.09
Cancelled.............................................. (37,084) 1.56
---------
Outstanding at December 31, 2004......................... 2,707,717 2.12
---------
Granted................................................ 853,000 4.46
Exercised.............................................. (167,881) 2.01
Cancelled.............................................. (33,501) 2.42
---------
Outstanding at December 31, 2005......................... 3,359,335 2.71
=========
OPTIONS EXERCISABLE
OPTIONS OUTSTANDING ---------------------- -------
----------------------------------------------------------------------------------- WEIGHTED
REMAINING WEIGHTED NUMBER AVERAGE
RANGE OF NUMBER OF CONTRACTUAL EXERCISE OF EXERCISE
EXERCISE PRICES OPTIONS LIFE PRICE OPTIONS PRICE
--------------- --------- ------------- -------- --------- --------
$ .55 to $1.50 655,667 1.6-7.0yrs. $ .77 655,667 $ .77
$1.81 to $2.79 1,406,668 2.5-9.5 yrs. $2.27 1,406,668 $2.27
$3.00 to $4.55 1,297,000 1.6-10.0 yrs. $4.18 1,297,000 $4.18
--------- ---------
Total 3,359,335 7.6 yrs. $2.71 3,359,335 $2.71
The per share weighted average fair values at the date of grant for the
options granted to employees during the years ended December 31, 2005 and 2004
were $4.46 and $3.17 respectively. For the period ended December 31, 2005, the
fair value was determined using the Black Scholes option pricing model using the
following assumptions: dividend yield of 0.0 percent, risk free interest rates
of 3.8-4.33 percent, volatility of 70% and expected lives of .5-3.0 years. For
the period ended December 31, 2004, the fair value was determined using the
Black Scholes option pricing model using the following assumptions: dividend
yield of 0.0 percent, risk free interest rates of 1.6-3.2 percent, volatility of
94% and expected lives of 2.0-3.0 years.
As of December 31, 2005, the remaining number of stock options available
for future grants was 233,856.
15. RELATED PARTY TRANSACTIONS
During the years ended December 31, 2005 and 2004, we had revenue from
companies in which our outside directors held an equity interest. Mr. Kenneth L.
Holt, a director of the Company as of March 14, 2000, held an equity interest in
certain customers of ours of which he divested such interest during 2005.
Revenue from these entities was $42,000 and $119,000 in 2005 and 2004,
respectively. Mr. Ronald D. Boyd, a director of the Company as of March 14, 2000
, held an equity interest in certain customers of our products during 2004.
Revenue from these entities aggregated $15,000 in 2004.
16. SUPPLEMENTAL CASH FLOW INFORMATION
We entered into non-cash transactions described below during the years
ended December 31, 2005 and 2004 which have not been included in the
Consolidated Statement of Cash Flows.
We entered into capital leases on equipment with a cost of $486,806 and
$315,282 for the years ended December 31, 2005 and 2004, respectively, and
financed those with capital lease obligations.
F-15
ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
17. SUBSEQUENT EVENT -- WARRANT OFFERING COMPLETION
We raised gross proceeds of $9,363,982 with the completion of our warrant
offering on January 26, 2006. We issued 2,401,021 Common Shares resulting from
New Warrant exercises of which 58,615 were issued in 2005 and the remainder in
January 2006. All unexercised publicly traded warrants expired on January 26,
2006. Gross proceeds of the offering were offset by costs of the offering. In
2005, the gross proceeds of $228,599 were entirely offset by costs of the
offering.
18. RECENT ACCOUNTING PRONOUNCEMENTS
In December 2004, the Financial Accounting Standards Board ("FASB") issued
Statement No. 123R ("SFAS 123R"), a revision to Statement No. 123, "Accounting
for Stock-Based Compensation." This standard requires us to measure the cost of
employee services received in exchange for equity awards, including stock
options, based on the grant date fair value of the awards. The cost will be
recognized as compensation expense over the vesting period of the awards. The
Company is required to adopt SFAS 123R beginning January 1, 2006. The standard
provides for a modified prospective application. Under this method, the Company
will begin recognizing compensation cost for equity based compensation for all
new or modified grants after the date of adoption. In addition, the standard
requires the Company to recognize compensation cost for the remaining unvested
portion of prior option grants over the remaining service period. However, all
of the Company's options granted in 2005 and prior years have been fully vested
as of December 31, 2005, and therefore, the Company will not record any expense
for options granted prior to 2006.
In November 2004, the FASB issued SFAS No. 151, "Inventory Costs" ("SFAS
151"). SFAS 151 requires that abnormal amounts of idle facility expense,
freight, handling costs, and spoilage, be charged to expense in the period they
are incurred rather than capitalized as a component of inventory costs.
Statement 151 is effective for inventory costs incurred after January 1, 2006.
We do not anticipate any material impact from this statement on our financial
statements.
F-16
EXHIBIT INDEX
EXHIBIT DESCRIPTION
------------ -----------
3(i).1 Articles of Incorporation of the Company, incorporated by reference
to Exhibit 3(i).1 to the Company's Registration Statement on Form SB-
2, File No. 333-31991.
3(i).2 Certificate of Amendment to Articles of Incorporation of the Company,
incorporated by reference to Exhibit 3(i).2 to the Company's
Registration Statement on Form SB-2, File No. 333-31991.
3(i).3 Certificate of Correction to Articles of Incorporation of the
Company, incorporated by reference to Exhibit 3(i).3 to the Company's
Registration Statement on Form SB-2, File No. 333-31991.
3(i).4 Certificate of Amendment to Articles of Incorporation of the Company,
incorporated by reference to Exhibit 3(i).4 to the Company's
Registration Statement on Form SB-2, File No. 333-31991.
3(ii) Bylaws of the Company, incorporated by reference to Exhibit 3(ii) to
the Company's Registration Statement on Form SB-2, File No. 333-
31991.
10.1 Rockwell Medical Technologies, Inc. 1997 Stock Option Plan,
incorporated by reference to the Proxy Statement for the Annual
Meeting of Shareholders filed on April 21, 2005.
10.2 Lease Agreement dated March 12, 2000 between the Company and DFW
Trade Center III Limited Partnership incorporated by reference to the
annual report on Form 10-KSB filed March 30, 2000.
10.3 Lease Agreement dated October 23, 2000 between the Company and
International-Wixom, LLC Incorporated by reference to the quarterly
report on Form 10-QSB filed November 14, 2000.
10.4 Licensing Agreement between the Company and Ash Medical Systems, Inc.
dated October 3, 2001 with certain portions of the exhibit deleted
under a request for confidential treatment under rule 24b-2of the
Securities Act of 1934 incorporated by reference to the annual report
on form 10-KSB filed April 1, 2002.
10.5 Licensing Agreement between the Company and Charak LLC and Dr. Ajay
Gupta dated January 7, 2002 with certain portions of the exhibit
deleted under a request for confidential treatment under rule 24b-2of
the Securities Act of 1934 incorporated by reference to the annual
report on form 10-KSB filed April 1, 2002.
10.6 Supply Agreement between the Company and DaVita, Inc. dated March 7,
2003 with certain portions of the exhibit deleted under a request for
confidential treatment under rule 24b-2 of the Securities Act of 1934
incorporated by reference to the annual report on form 10-KSB filed
March 28, 2003.
10.8 Supply Agreement between the Company and DaVita, Inc. dated May 5,
2004 with certain portions of the exhibit deleted under a request for
confidential treatment under Rule 24b-2 of the Securities Exchange
Act of 1934 incorporated by reference to the quarterly report on Form
10-QSB filed on May 17, 2004.
10.9 Loan and Security Agreement dated as of March 29, 2005 between the
Company and Standard Federal Bank National Association incorporated
by reference to the annual report on form 10-KSB filed arch 31, 2005.
10.10 Revolving Note dated as of March 29, 2005 executed by the Company for
the benefit of Standard Federal Bank National Association
incorporated by reference to the annual report on form 10-KSB filed
March 31, 2005.
10.11 Unconditional Guaranty dated as of March 29, 2005 executed by
Rockwell Transportation, Inc. for the benefit of Standard Federal
Bank National Association incorporated by reference to the annual
report on form 10-KSB filed March 31, 2005.
10.12 Second Amendment of Industrial Lease Agreement between Rockwell
Medical Technologies, Inc. and DCT DFW, LP dated August 17, 2005,
incorporated by reference to Exhibit 99.1 on Form 8-K filed on August
19, 2005.
10.13 Amending Agreement made the 16th day of January, 2006, by and between
Dr. Ajay Gupta, Charak LLC and Rockwell Medical Technologies, Inc.
EXHIBIT DESCRIPTION
------------ -----------
14.1 Rockwell Medical Technologies, Inc. Code of Ethics incorporated by
reference to the Definitive Proxy Statement for our 2004 Annual
Meeting of Shareholders filed April 23,2004.
21.1 List of Subsidiaries incorporated by reference to Exhibit 21.1 to the
Company's Registration Statement on Form SB-2, File No. 333-31991.
23.1 Consent of Plante & Moran, PLLC.
31.1 Certifications of Chief Executive Officer Pursuant to Rule 13a-14(a),
as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 Certifications of Chief Financial Officer Pursuant to Rule 13a-14(a),
as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 Certifications of the Chief Executive Officer and Chief Financial
Officer, Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.